Cel Sci ◄◄Warten auf die FDA►► Kursziel 5$ - 500 Beiträge pro Seite

[[KERN]Codex]

CEL-SCI Rockets Higher

Tuesday, biotech CEL-SCI (AMEX: CVM) traded up to 92 cents. We Alerted the readership a scant two weeks ago when the shares were idling at 52-cents. At this writing the shares are trading strongly at 84-85 cents on significant volume—a rise of over 60 percent since February 10th.
What to do now? Depends on whether you’re a trader or an investor.

The Company also announced today (release below) the issuance of another significant US patent regarding its LEAPS (Ligand Epitope Antigen Presentation System) technology platform for Autoimmune Conditions and Allergies. A discussion of this announcement follows our technical picture.

There is little doubt that the shares of CVM have had an excellent early run. We believe that there is much more to come for CEL-SCI shares. What to do now depends on your perspective. As we have stated, the 83-85-cent level represents a technical resistance level. Traders might want to lighten up a tad and wait for either a 3/8 or 5/8 pullback as shown on the chart to fill in positions, but should maintain a decent core holding. Long-term investors should likely hold here and both groups should buy on dips should they occur. We see good upside potential for the shares, but we’d also like to see a sustained move above current levels at which time we will reassess our targets.

Given the volatility of these shares, as with most small caps, long-term investors—whether adding to or initiating a position--should always employ a physical or mental stop loss to protect capital/profits.

More and Better.

The newly issued patent announced today addresses the pretreatment and early therapy of Experimental Autoimmune Myocarditis with a compound developed by CEL-SCI resulted in significant reduction in heart enlargement and disease associated histopathological changes in mice. The detailed discussion of this significant development is in the release and I would direct you to give it a careful read, but the salient point is that:

“These findings could potentially lead to the development of a treatment for autoimmune myocarditis, a life threatening heart disease, which is characterized by an enlarged and weakened heart. Myocarditis is a precursor to dilated cardiomyopathy, a condition leading to a form of chronic heart failure (CHF) characterized by an inflamed heart. End stage CHF requires a heart transplant or death ensues.”

It is apparent that news and developments are increasing the visibility of CEL-SCI as evidenced by the both the rising daily volumes and increased share price. As we have noted, the discounted market cap of CVM when compared to a number of biotech peers should-- and may well already --be in the process of coming into line as investors weigh the commercial potential of the diverse and unique product mix of the company.

CVM’s addressing of some of society’s most devastating diseases with novel immunology-based therapies appears to be gaining the attention of investors as it moves closer to Phase 3 trials, increases its patents and continues its robust R&D.

The potential for CVM’s technologies to use the immune system as a disease fighter represents a new therapeutic direction from the standard toxic, end-of-life, chronic disease management drugs/therapies of the Big Pharma companies.

From the release:

Therefore, L.E.A.P.S. is thought to be a delivery vehicle that directs or controls the immune response to the desired outcome. This ability to preferentially direct the immune system is a major breakthrough. Any diseases for which antigenic epitope sequences have been identified, such as infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, are potential candidates for this technology.

Those investors who wish to participate in this new generation of drugs/therapies would, we believe, be well served in the long-term by including CEL-SCI within the smallcap biotech section of a portfolio.

PRESS RELEASE

CEL-SCI Receives U.S. Patent for Use of L.E.A.P.S(TM) Technology for Autoimmune Conditions and Allergies

Feb 28, 2006 10:28:00 AM
VIENNA, Va., Feb. 28 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) has been issued a U.S. patent covering its L.E.A.P.S.(TM) peptide vaccine technology in the areas of autoimmunity and allergies. The new patent, U.S. Patent No. 6,995,237, is titled, " Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions." The L.E.A.P.S. technology has also produced the patented CEL-1000 drug, which induced protection in animals against viruses and parasites and is being tested by the National Institute of Allergy and Infectious Diseases against the avian flu virus.

This new patent builds on work by CEL-SCI scientists in collaboration with scientists from the laboratory of Dr. Noel Rose at The Johns Hopkins University Department of Pathology, showing that pretreatment and early therapy of Experimental Autoimmune Myocarditis with a compound developed by CEL-SCI resulted in significant reduction in heart enlargement and disease associated histopathological changes in mice. The compound used was derived from CEL-SCI`s patented L.E.A.P.S. (Ligand Epitope Antigen Presentation System) platform technology.

These findings could potentially lead to the development of a treatment for autoimmune myocarditis, a life threatening heart disease, which is characterized by an enlarged and weakened heart. Myocarditis is a precursor to dilated cardiomyopathy, a condition leading to a form of chronic heart failure (CHF) characterized by an inflamed heart. End stage CHF requires a heart transplant or death ensues. The incidence in the United States alone of dilated cardiomyopathy is about 200,000 people.

The protection against experimentally induced myocarditis was statistically significant for both pretreatment and early therapy with the L.E.A.P.S compound. The response was antigen-specific and was associated with an increase in IL-13 in both the sera and heart tissue and of IL-1 alpha in the sera of the protected mice. Other studies from Dr. Rose`s laboratory with IL-13 knockout-mice (mice missing the IL-13 gene) demonstrated the importance of IL-13 in this animal model of Experimental Autoimmune Myocarditis.

Dr. Daniel H. Zimmerman, Senior Vice President Research, Cellular Immunology, at CEL-SCI said, " These studies showed that we are able to treat mice with ongoing heart disease. This may lead to treatment of autoimmune myocarditis in humans where the disease process is similar to the animal model being studied and reported here. The issuance of a U.S. patent protecting our novel work is very critical to our effort."

The most well-known and common autoimmune diseases are insulin dependent diabetes mellitus, rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel and Graves Disease. A common thread among these diseases is an immune response that " perceives" the person`s own body, cells and organs as foreign. This, in turn, results in relentless attacks by the person`s own immune system against his/her own body, eventually leading to debilitating disease, and occasionally to death. Likewise, the rejection in transplant condition is an immunologically based reaction. In immune mediated allergic reactions the L.E.A.P.S. vaccine is intended to redirect the immune response away from the harmful response in humans to a more subdued response that is not harmful. Current therapies for these conditions generally treat the symptoms of the disease but not the underlying cause of the disease as is done with the L.E.A.P.S. vaccine.

L.E.A.P.S. is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. L.E.A.P.S. compounds (" constructs" ) consist of a peptide epitope associated with a disease-causing agent linked to a T-cell binding peptide ligand (TCBL). Together they induce the immune system to mount either a cellular (e.g., T-cell), humoral (antibody) or a mixed immune response as a means to treat, control or prevent disease. Therefore, L.E.A.P.S. is thought to be a delivery vehicle that directs or controls the immune response to the desired outcome. This ability to preferentially direct the immune system is a major breakthrough. Any diseases for which antigenic epitope sequences have been identified, such as infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, are potential candidates for this technology. More information on L.E.A.P.S. is available at http://www.cel-sci.com.

The myocarditis work was supported in part by grants HL071352-01A1, HL67290, HL70729, AI51835 and HL077611 from National Heart, Lung and Blood Institute (NHLBI) and National Institute of Allergy and Infectious Diseases, Institutes of the National Institutes of Health (NIH).

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company`s lead product Multikine(R) is cleared to enter Phase III clinical trials with advanced primary head and neck cancer patients. Other products, in the pre-clinical stage and funded with U.S. government support, have induced protection against a number of diseases in animal tests and are being tested against diseases associated with bio- defense and avian flu.

SOURCE CEL-SCI Corporation

[[KERN]Codex]

Angriff auf unser Immunsystem?

Die Vogelgrippe weitet sich aus – Ängste einer bevorstehenden Pandemie!

Die Vogelgrippe (aviäre Influenza; Geflügelpest) ist eine durch ein Virus mit der Bezeichnung H5N1 hervorgerufene anzeigepflichtige Tierseuche, von der Hühner, Puten, Gänse, Enten und wildlebende Vögel betroffen sind. Es sind fünf Virusstämme bekannt, von denen das H5N1 das gefährlichste ist. Eine Infektion mit den aggressiveren Virusstämmen führt zum Tod der betroffenen Vögel. Erkrankte Vögel werden apathisch, bekommen Fieber, Atembeschwerden und Durch- fall. Nach einer Inkubationszeit von einigen Tagen sind fast alle Tiere im Bestand infiziert. Sie legen keine Eier mehr und sterben nach kurzer Zeit. Die Vogelgrippe ist auf den Men- schen übertragbar; die Moralität (Sterblichkeit) ist sehr hoch. Die Bedingungen des Überspringens des Virus auf den Men- schen sind jedoch nach wie vor ungeklärt. Gefahr für den Menschen besteht vor allem bei gleichzeitiger Infektion mit einer "normalen" Influenza, da in diesem Fall sein Immun- system geschwächt ist. Trotz erheblicher Anstrengungen konnte die die Ausbreitung der Vogelgrippe nicht gestoppt werden. Für die unaufhaltsame Verbreitung sorgen Zugvögel, Aasfresser, der sorglose Umgang mit infiziertem Geflügel und der internationale Handel mit Geflügel. Die Situation verschärft sich aus mehreren Gründen: Das Virus H5N1 wurde 2004/2005 in Schweinen nachgewiesen und bestimmte Vogelarten sind widerstands- kräftiger gegenüber der Seuche geworden - dienen also länger als Virenausscheider. Die asiatischen und kleinasiatischen Staaten, in denen die Vogelgrippe aufgetreten ist, haben z. T. nicht angemessen auf die Seuche reagiert. Aus Angst vor Image-Schäden hielt man wichtige Informationen zurück. Traditionen bei der Haltung von Geflügel erwiesen sich als stärker als die Angst vor Ansteckung. Dies hat das Fortschreiten der Seuche begünstigt. Die Vogelgrippe hat Europa erreicht und breitet sich zurzeit in Deutschland aus. Das Auftreten der Vogelgrippe in Deutschland ist von Diskussionen über mangelndes Krisenmanagement begleitet.


Die Ansteckungsgefahr

Die Vogelgrippe ist zwar direkt auf den Menschen übertragbar, jedoch nur bei ständigem engem Kontakt zu infizierten Nutzvögeln. Ist das Immunsystem des Menschen, etwa durch eine "gewöhnliche" Influenza, geschwächt, erleichtert dies dem Virus das Eindringen in den menschlichen Organismus. Ansteckungsgefährdet sind vor allem jene Menschen, die auf engstem Raum mit lebendem Geflügel arbeiten. Die Übertragung von Mensch zu Mensch ist nicht sicher nachgewiesen und scheint sich auf Fälle intensiven Kontakts mit infizierten Familienmitgliedern zu beschränken. Was viele Wissenschaftler fürchten: Das beherrschbare Influenza-Virus und das Vogelgrippe-Virus tauschen ihr Erbgut aus und bilden dabei ein neues Virus, welches von Mensch zu Mensch übertragbar ist.


Gibt es einen Impfstoff gegen die Vogelgrippe?

Bislang gibt es keinen Impfstoff für den Fall einer Grippepandemie. Auch an einem Impf- stoff für Geflügel wird derzeit noch gearbeitet. Die antiviralen Medikamente Tamiflu und Relenza gelten aber als viel versprechende Mittel bei der Bekämpfung der Seuche. Sie sollten bei den ersten Anzeichen einer Vogelgrippe-Erkrankung eingenommen werden und können auch präventiv eingesetzt werden. Das Bundesgesundheitsministerium rät Privat- leuten jedoch davon ab, sich antivirale Medikamente selbst zu kaufen. Tamiflu und Relen- za sollte nur unter ärztlicher Kontrolle eingenommen werden. Nichts desto Trotz sind Medi- kamente in Apotheken mittlerweile vergriffen.

Ein Unternehmen, das durch die Stimulierung des Immunsystems in Zukunft möglicherweise virale und mikrobielle Infektionen, wie z.B. die Vogelgrippe, effektiv bekämpft könnte, möchten wir Ihnen heute vorstellen. Erst letztes Jahr erhielt man die hierfür notwendige Patentierung von CEL-1000.

[[KERN]Codex]

Gigantisches Volumen Heute => 1,823,100 Mio Stücke wurden an der AMEX gehandelt

[Mannitrader]

[[KERN]Codex]

Company Profile
Datum der Veröffentlichung: 16.02.2006


Basis Informationen
Anzahl Aktien in Mio.: ca. 77,97
Reuters Symbol: CVM.A
Börsenwert in EUR Mio.:ca. 57,5
Tagesumsatz Ø 3M:221.644 Aktien AMEX
Streubesitz:ca. 94%
Börse Frankfurt Symbol:LSR.FSE
Grossaktionäre:Geert Kersten 3,4 % +KERNI
ISIN US1508374097
Hauptbörse:AMEX
WKN:871 006
Info: www.cel-sci.com Geschäftsjahr zum: 30.09.

Die CEL-SCI Corp. hat von der kanadischen Behörde „Biologics and Genetics Therapies Directorate“ (BGTD) die Bestätigung zur Durchführung klinischer Phase-III-Studien mit Multikine in Kanada erhalten. Die erfolgreiche Beantragung basiert unter anderem auf Ergebnissen der Phase-II-Studie, die in der renomierten Fachzeitschrift Journal of Clinical Oncology im Mai des letzten Jahres veröffentlicht wurden. Eine entsprechende Genehmigung von Phase-III-Studien zur Anwendung von Multikine „bei der Behandlung von fortgeschrittenem, primären Plattenepithelkarzinomen der Mundhöhle“ durch die US amerikanische Gesundheitsbehörde FDA (Food and Drug Administration) steht zwar aus, wird aber noch im Verlauf dieses Jahres erwartet. Damit könnte die CEL-SCI Corp zu den wenigen Biotechnologiefirmen aufschließen, die ein neuartiges Krebspräparat in der späten klinischen Entwicklung haben und sich damit - vor Mitbewerben - einen wichtigen strategischen Vorteil sichern. Darüber hinaus wartete die Firma Ende letzten Jahres mit der Patentierung von CEL-1000 auf, mit dem durch Stimulation des Immunsystems in Zukunft möglicherweise virale und mikrobielle Infektionen – Stichwort: Vogelgrippe - effektiv bekämpft werden können.

CEL-SCI Corp.


Zurück auf dem Radar-Schirm!

Genehmigung für Phase-III-Studie von Multikine in Kanada und Patentierung von CEL-1000 läuten eine neue Phase in der Firmengeschichte ein

Rating (12M):Spekulativ Kaufen
seit 26.03.2004
Letzte Ratingänderung:keine
Kursziel:€ 2,35
seit:26.03.2004
Kurs (15.02.2006, 17:04 STU):€ 0,43
Hoch/Tief 250 Tage:€ 0,57/ 0,37
Nächstes Research:in Vorbereitung

Analyst: Dipl.-Bio. Claudia Meissner
- Finanzanalystin -
Telefon: (+49) (0) 621 / 43061-30
Email: [e-mail]
Company Profile


Die CEL-SCI Aktie – Der Dornröschenschlaf ist vorbei

MIDAS Research verfolgt die spannende Entwicklung bei CEL-SCI nun bereits im dritten Jahr und hat immer wieder auf die entscheidenden Schritte in der Unternehmensentwicklung hingewiesen. So zuletzt geschehen in unserem Update vom 31. Januar 2005. Doch gut Ding braucht bekanntlich Weil, vor allem in der Biotechnologie. Das Jahr 2005 hat CEL-SCI insbesondere damit zugebracht bzw. zubringen müssen, die bisherigen Forschungsergebnisse in den anerkannten Fachzeitschriften und Forscherzirkeln angemessen zu verbreiten und publik zu machen. Diese Image-Arbeit ist unerlässlich auf dem Weg zur Kür, d.h. der alles entscheidenden klinischen Forschungsphase-III, an deren Ende dann die ersehnte Marktzulassung stehen sollte. Diese Phase-III, die immerhin 500 Patienten umfassen wird, muss entsprechend sorgfältig vorbereitet werden und beinhaltet im Vorfeld insbesondere umfangreiche Konsultationen mit der amerikanischen Zulassungsbehörde FDA. Diese zeitraubende Tätigkeit hat folglich einen Großteil der Arbeit der Wissenschaftler von CEL-SCI im vergangenen Jahr ausgemacht.
Leider ist diese Arbeit aus Börsensicht weniger attraktiv, da nachrichtenarm. Aber es hat sich gelohnt, denn inzwischen kann CEL-SCI bereits eine Phase-III-Zulassung für Kanada vorweisen, so dass die FDA nicht mehr lange auf sich warten lassen sollte.
Bei unserer ursprünglichen Analyse des mit Multikine verbundenen Ertragspotenzials haben wir seinerzeit (März 2004) einen Ertragswert von USD 2,79 je Aktie ermittelt, wobei wir entsprechend dem damaligen klinischen Entwicklungsstand von Multikine nur von einer Wahrscheinlichkeit von 50% ausgegangen sind, dass das Präparat auch tatsächlich auf den Markt gelangen wird. Bei einem Phase-III-Produktkandidaten liegt die Zulassungswahrscheinlichkeit jedoch bedeutend höher zwischen 70 und 80 Prozent, so dass sich der Ertragswert ebenfalls entsprechend erhöhen wird, sobald die Genehmigung durch die FDA vorliegt. Diese ist insbesondere wichtig wegen des lukrativen US-amerikanischen Pharmamarktes.
Es bleibt ein Faktum, dass der Aktienkurs das Ertragspotenzial eines primär forschenden Biotech-Unternehmens oft nur eingeschränkt widerspiegelt, obwohl wir dem Risiko ja etwa schon über den Abzinsungsfaktor bzw. über unterschiedliche Zulassungswahrscheinlichkeiten Rechnung getragen haben. Unabhängig davon halten wir es allerdings für mehr als wahrscheinlich, dass der stark gedrückte Aktienkurs von CEL-SCI auf die Nachricht einer FDA-Zulassung einer Phase-III-Studie für Multikine – oder eine vergleichbare Nachricht, die als weitere signifikanter „Proof-of-concept“ zu sehen ist – mit erheblichen Aufschlägen reagieren wird. Wann es soweit sein wird, bleibt natürlich weiter ungewiss, doch angesichts der über die letzten 12 Monate geleisteten Arbeit sollte u.E. der Zeitpunkt nicht mehr fern sein. Höchste Zeit also, CEL-SCI wieder auf den Radarschirm bzw. ins Depot zu nehmen!


CEL-SCI – Die Immunsystemspezialisten oder: Was bisher geschehen ist

Das 1983 gegründete US-amerikanisches Biotechnologie-Unternehmen CEL-SCI Corp. mit Sitz an den Standorten Vienna (Virginia) und Baltimore (Maryland) entwickelt immuntherapeutische Verfahren zur Bekämpfung von Krebs und Infektionserkrankungen. Das Grundprinzip der entwickelten Wirkstoffe ist hierbei die mögliche Stimulation des körpereigenen Immunsystems gegen Krebszellen sowie Bakterien (z.B. Tuberkulose), Viren (H5N1, HIV, HPV) oder Parasiten (Malaria). Das Unternehmen verfügt hierbei zurzeit über zwei eigene Entwicklungslinien, die sich in unterschiedlichen klinischen Testphasen befinden: Multikine und CEL-1000 bzw. die L.E.A.P.S. Technologie.

Bei Multikine handelt es sich um einen natürlichen Mix von Immun-Modulatoren, die aus Humanzellen über ein komplexes Isolationsverfahren gewonnen werden. Die positive Wirkeigenschaft von einzelnen Immun-Modulatoren wie z.B. dem Interleukin-2 im Kampf gegen Krebszellen ist seit einiger Zeit bekannt. Aufgrund der Komplexität des menschlichen Immunsystems ist der Effekt durch die Gabe von einzelnen immunstimulierenden Wirkstoffen, die mittlerweile gentechnisch hergestellt werden können, aber begrenzt. Das von CEL-SCI Corp. produzierte Multikine enthält daher eine breite Palette von natürlichen Immun-Regulatoren, die auf unterschiedlichen zellulären Ebenen für eine Immunreaktion des Körpers gegen entartete Körperzellen wirken können.
Die CEL-SCI Corp. Wissenschaftler um Eyal Talor sowie Wissenschaftler des Institutes für Onkologie der Semmelweis Universität Budapest haben in der Fachzeitschrift Journal of Oncology der American Society of Clinical Oncology erstmals die vollständigen Ergebnisse der klinischen Phase-II-Studie von Multikine in der Therapie von aggressiven Platten-epithelkarzinomen der Mundhöhle veröffentlicht und Modelle zur Wirkweise von Multikine präsentiert. Die Ergebnisse deuten darauf hin, dass die in Multikine enthaltenen Immunmodulatoren zur Infiltration (Einwanderung) von wichtigen „Abwehr“-Zellen des Immunsystems in den Tumor führen und die Krebszellen abtöten. 42 Prozent der über drei Wochen mit Multikine behandelten Patienten sprachen auf die Behandlung an, wobei es bei 12% (2/19) der Patienten zu einem kompletten Rückgang des Tumors kam. Die Wirkungsweise von Multikine wird von den Wissenschaftlern zurzeit in einem Modell als komplexer mehrstufiger Prozess untergliedert.
Multikine – Hilfe zur Selbsthilfe oder: Wie funktioniert das?
In Multikine vorhandene Tumornekrosefaktoren (z.B. TNF-alpha) führen zu einer Freisetzung von Tumorantigenen (tumorspezifische Proteine), die von speziellen Zellen des Immunsystems wie z.B. dentritischen Zellen aufgenommen werden und diese auf der Oberfläche abbilden. Die Freisetzung und Oberflächenpräsentation von tumorspezifischen Antigenen ist eine wichtige Voraussetzung zur generellen Aktivierung einer Immunantwort gegen die Tumorzellen und kennzeichnet die entarteten Zellen als „nicht eigen“. Tumor-antigenpräsentierende Zellen wandern in die Lymphknoten. In den Lymphknoten kommt es dann durch spezifische Cytokine aus dem Multikine-Mix zur Induktion einer starken Vermehrung von tumorspezifischen T-Zellen, die durch den Kontakt mit Tumor-antigenpräsentierenden Zellen aktiviert werden. CD4 T-Helferzellen werden dann aus den Lymphknoten durch chemotaktische Faktoren in den Tumor gelenkt, wobei es zu einer Umkehrung des Verhältnisses von T-Helferzellen (CD4) und cytotoxischen T-Zellen (CD8) kommt, sodass mehr CD4 als CD8-Zellen im Tumorgewebe vorliegen. Dies soll zu einer weiteren Zerstörung von Tumorzellen führen und mit den identifizierten Nekrosen im entfernten Tumorgewebe korrelieren. Außerdem induziert der in Multikine vorliegende Modulator GM-CSF eine Rekrutierung von neutrophilen Lymphozyten, die ebenfalls zu einer Zerstörung der Tumorzellen führt.
Letztendlich glauben die CEL-SCI Wissenschaftler, dass es durch die Cytokingaben in Multikine sowie durch die Induktion der Cytokinproduktion von in den Tumor eingewanderten Immunzellen zu einer massiven Fibrose kommt. Hierbei wandern Bindegewebszellen (Fibroblasten) in den Tumor und sind für die Narbenbildung verantwortlich.
Die Patientengruppe, die nicht auf Multikine ansprach, konnte als MHCII negativ getestet werden. Der MHC (Major Histocompatibility Complex) ist für eine Aktivierung der Immunzellen gegen das Tumorgewebe notwendig und befindet sich auf allen Körperzellen. Ein Fehlen dieses Komplexes auf den entarteten Zellen stellt ein großes Hindernis für alle immuntherapeutische Verfahren da. Die CEL-SCI Wissenschaftler sehen jedoch in dem Untersuchungsbefund die Möglichkeit, das Fehlen des MHCII-Komplexes als Marker zu verwenden. Damit können die Patienten gezielt behandelt werden, die auf eine Multikine-Therapie mit großer Wahrscheinlichkeit ansprechen.


Klinische Phase-III könnte Weg zur Universalwaffe gegen Krebs ebnen

Bereits in einer früheren Veröffentlichung konnten die CEL-SCI Wissenschaftler außerdem Krebszellen durch Multikinegaben für chemo- und radio-therapeutische Maßnahmen erfolgreich sensibilisieren. Beide Effekte, die durch Multikine generierte Infiltration von Immunzellen in den Tumor und die damit in Verbindung stehenden weiteren Reaktionen sowie die Sensibilisierung von Tumorzellen für radio- und chemotherapeutische Ansätze, scheinen nicht auf Plattenepithelkarzinome der Mundhöhle beschränkt zu sein. Es ist daher wahrscheinlich, dass Multikine zur grundsätzlichen Therapieunterstützung gegen diverse Krebserkrankungen einsetzbar ist. Auf der Basis der publizierten Daten bestätigte die zuständige kanadische Gesundheitsbehörde „Biologics and Genetics Therapies Directorate“ (BGTD) die Durchführung von Phase-III-Studien in Kanada. Eine Bestätigung der amerikanischen „Food and Drug Administration“ steht bislang aus, wird aber noch in diesem Jahr erwartet. Damit erhält das Unternehmen mit seinem asiatischen Partner Orient EuroPharma die Möglichkeit, eine umfassende klinische Phase-III-Studie (ca. 500 Patienten) in Amerika, Europa und Asien durchzuführen, um die Wirksamkeit von Multikine auf breiter Basis zu bestätigen und ein Produkt nach 20 Jahren Forschung auf den Markt zu bringen. Die Rechte an Multikine konnte CEL-SCI Corp. durch das US Patent No. 6.896.879 im letzten Jahr erfolgreich verlängern.
Ein weiteres Patent (US No. 6.951.647) wurde der CEL-SCI Corp. im November 2005 für CEL-1000 erteilt. Dieses Produkt basiert auf einem natürlichen Eiweiß des Immunsystems, das spezifisch an humane Immunzellen bindet und somit spezifische Abwehrreaktionen gegen Viren, Bakterien und Parasiten auslösen kann. Das Produkt befindet sich in der präklinischen Phase. CEL-SCI Corp hat im Dezember 2005 mit dem „National Institute of Allergy and Infectious Disease“ (NIAID) ein Kooperationsabkommen geschlossen, das CEL-1000 auf die mögliche Wirksamkeit gegen das sich global ausbreitende „Vogel“-Grippe-Virus H5N1 testet.


Fazit
Mit dem vorliegenden Company Profile wollten wir einen kurzen Abriss über die operativen Fortschritte bei der CEL-SCI Corp. im abgelaufenen Jahr bzw. Anlegern, die das Unternehmen bisher noch nicht kennen, eine kurze Einführung in das Unternehmen geben. Wir hoffen klar gemacht zu haben, dass CEL-SCI nach einer länger als von uns gedachten Phase der Arbeiten an einer FDA-Genehmigung für die abschließenden klinischen Studien nun wieder auf den Radar-Schirm genommen werden sollte. U.E. ist CEL-SCI inzwischen in einem Unternehmensstadium angelangt, indem jederzeit wieder mit Kurs treibenden Meldungen gerechnet werden kann. Somit bleibt es auch bei unserer Einstufung als „Spekulativer Kauf“. Unser bisheriges Kursziel von USD 2,80 (EUR 2,35) bleibt zunächst unverändert, würde aber dann kurzfristig an die aktuelle Nachrichtenlage angepasst und zusammen mit unserem Bewertungsmodell in einer ausführlicheren Studie im Detail erläutert.


Pflichtlektüre

http://www.more-ir.de/d/10122.pdf

Viel Spaß damit,

könnte so abgehen wie Mologen, wenn die FDA ihr OKAY gibt

[Lanzalover]

und ich habe mich schon gewundert, wann du einen thread zu denen aufmachst . . .

[mfierke]

das liest sich ja alles sehr gut, die aber auch schon gut gelaufen, nur grüne Balken, ich werde sie mal auf die WL legen, schön über wachen

[AlfredBiophan]

sauber Kerni, schöne DD

[volkerg]

Kerni, du bist ein Bio-Gott!

[zakk60]

[posting]20.435.681 von mfierke am 01.03.06 07:22:35[/posting]Tach Frau von und zu - auch hier?

Was macht eigentlich Primac. ich bin dort seit einem
Monat endgültig raus. Ging ja nur noch Richtung
Süden.

[Certi]

Hallo!
Hier trifft sich ja der "harte Kern" von Mologen !! Schön alle wiederzusehen.
Die Aktie finde ich interessant - aber schon sehr gut gelaufen -warte auf die nächste Reaktion!

[Lanzalover]

[posting]20.438.411 von Certi am 01.03.06 10:46:43[/posting]geht mir genauso . . .

[[KERN]Codex]

Einfach laufen lassen, bin gespannt auf die vorbörslichen Kurse an der AMEX



Schon lustig wieviele alte Bekannte hier sind - ich denke es werden noch mehr wenns hier richtig losgeht

[[KERN]Codex]

Frankfurt

Letzter Kurs 0,82 k.A.
Geld 0,80 42.000 St.
Brief 0,83 8.000 St.

[[KERN]Codex]

[posting]20.434.981 von Lanzalover am 28.02.06 23:40:39[/posting]Die Ersten +60% von 55c auf 80c hab ich ewartet, weil es schon einen Thread gab,..
da sie doch tatsächlich jemand vor mir entdeckt hat! Und genau demjenigen hab ich es sehr gegönnt

[DRMARBUSE]

Klingt inter. Deshalb hab ich mir mal eben ein paar
ins Depot gelegt. Hoffe es war kein Fehler.

[[KERN]Codex]

Tageshoch in FFM

Letzter Kurs 0,83 k.A.
Geld 0,80 44.500 St.
Brief 0,84 3.000 St.

[[KERN]Codex]

p.s.

in Stuttgart gibts noch welche für 82c

Geld 0,81 5.000 St.
Brief 0,82 5.000 St.

[buxte]

sind ja wirklich viele Bekannte hier.

Ein Hallo an alle

buxte

[auric7]

nicht übel trotzdem stark über pari -ich wart mal 15:30 ab

[[KERN]Codex]

auric,

in den letzten tagen haben wir immer vorsprung gehabt, wenn wir Heute den Dollar knacken gehts verdammt schnell, dann bekommt CEL SCI erst richtig Aufmerksamkeit

Geld 0,80 42.000 St.
Brief 0,84 3.000 St.

[Iceman65]

welches KZ gibt es hier???

[[KERN]Codex]

CEL-SCI Corp. CEO Featured In Exclusive Interview With WallSt.net
Wednesday March 1, 7:00 am ET


NEW YORK, March 1 /PRNewswire/ -- On February 27, Geert Kersten, CEO of CEL-SCI Corp. (Amex: CVM - News) updated the investment community in an all-new, exclusive interview with www.wallst.net. Topics covered in the interview include an overview of the Company and the markets it serves, recent press releases, current capitalization, upcoming strategic and financial milestones.

To hear the interview in its entirety, visit www.wallst.net , and click on "Interviews/Podcasts". Interviews require free registration, and can be accessed either by locating the respective company`s ticker symbol under the appropriate exchange on the left-hand column of the "Interviews/Podcasts" section of the site, or by entering the respective company`s ticker symbol in the Search Archive window.

About CEL-SCI Corp.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company`s lead product Multikine® is cleared to enter Phase III clinical trials with advanced primary head and neck cancer patients. Other products, in the pre-clinical stage and funded with U.S. government support, have induced protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.

[[KERN]Codex]

Geld
0,80

Brief
0,84

Zeit
01.03.06 13:49:46

Geld Stk.
42.000

Brief Stk.
3.000

[Lanzalover]

[posting]20.441.763 von [KERN]Codex am 01.03.06 13:37:25[/posting].

das fand ich auch gerade . . .

habt ihr das drohende delisting von der amex schon thematisiert?
(da fehlt wohl ein filing und wenn das bis übermorgen nicht vorliegt, gibt´s ärger)

[[KERN]Codex]

[[KERN]Codex]

p.s.
08:37 $ .989 2,000
08:37 $ .98 1,000
08:34 $ .98 1,000
08:31 $ .95 1,500

[Lanzalover]

wo ist mein posting hin?

gelöscht?

wurde meine frage etwa als bashen aufgefasst?

also, ich bin an einem einstieg mehr als interessiert (schlage mit schon einige stunden mit dem thema um die ohren)

also noch mal;


in besagtem posting hatte ich gefragt, ob ihr das drohende delisting schon thematisiert habt?

...

As expected, CEL-SCI has received a letter from the AMEX stating that the Company will have to submit a plan by February 7, 2006 advising the AMEX of action CEL-SCI has taken, or will take, that would allow the Company to file the 10-K by no later than March 20, 2006. CEL-SCI has already indicated to the AMEX that it intends to submit such a plan. If the AMEX accepts CEL-SCI`s plan, CEL-SCI can maintain its AMEX listing during that time subject to the periodic determination by the AMEX that CEL-SCI is making progress consistent with the plan. If CEL-SCI`s plan is not accepted, CEL-SCI will be subject to delisting proceedings.

aus:

http://biz.yahoo.com/prnews/060125/dcw057.html?.v=37


und dann habe ich gelesen, das dieser plan zwar vorgelegt wurde aber nicht zzufriedenstellend war (?) und das cel sci nun nur noch bis übermorgen zeit hat zu ihr ´filing´ einzureichen, sonst droht das delisting


CEL-SCI submitted this plan to the AMEX on February 7, 2006. The plan indicated that it would file the 10-K by March 20, 2006. Since CEL-SCI does not have a completed 10-K, CEL-SCI was unable to file its quarterly report (10-Q) for the period ending December 31, 2005 in a timely manner either. This constitutes an additional deficiency under Section 134 and 1101 of the AMEX rules. CEL-SCI will now have to submit a plan to the AMEX by March 3, 2006 advising the AMEX of action CEL-SCI has taken, or will take, that would allow the Company to file the 10-Q by no later than April 6, 2006. If the AMEX accepts CEL-SCI`s plans, CEL-SCI can maintain its AMEX listing during that time subject to the periodic determination by the AMEX that CEL-SCI is making progress consistent with the plan. If CEL-SCI`s plan is not accepted, CEL-SCI will be subject to delisting proceedings.

http://www.finanznachrichten.de/nachrichten-2006-02/artikel-…


was haben die für probleme?


für eine antwort wäre ich sehr dankbar . . .

mfg.

lanzalover

[[KERN]Codex]

lanza,

die haben bis zum April Zeit(!) und sie versorgen die FDA gerad mit allen Daten die sie für die Zulassung benötigen.. die haben im Moment einfach besseres zu tun

Mundhöhlenkrebs Phase 3

FFM TH 0,83 EUR +9,21%



Ich erinnere nochmal an den gestrigen PRESS RELEASE:


The newly issued patent announced today addresses the pretreatment and early therapy of Experimental Autoimmune Myocarditis with a compound developed by CEL-SCI resulted in significant reduction in heart enlargement and disease associated histopathological changes in mice. The detailed discussion of this significant development is in the release and I would direct you to give it a careful read, but the salient point is that:

“These findings could potentially lead to the development of a treatment for autoimmune myocarditis, a life threatening heart disease, which is characterized by an enlarged and weakened heart. Myocarditis is a precursor to dilated cardiomyopathy, a condition leading to a form of chronic heart failure (CHF) characterized by an inflamed heart. End stage CHF requires a heart transplant or death ensues.”

It is apparent that news and developments are increasing the visibility of CEL-SCI as evidenced by the both the rising daily volumes and increased share price. As we have noted, the discounted market cap of CVM when compared to a number of biotech peers should-- and may well already --be in the process of coming into line as investors weigh the commercial potential of the diverse and unique product mix of the company.

CVM’s addressing of some of society’s most devastating diseases with novel immunology-based therapies appears to be gaining the attention of investors as it moves closer to Phase 3 trials, increases its patents and continues its robust R&D.

The potential for CVM’s technologies to use the immune system as a disease fighter represents a new therapeutic direction from the standard toxic, end-of-life, chronic disease management drugs/therapies of the Big Pharma companies.

From the release:

Therefore, L.E.A.P.S. is thought to be a delivery vehicle that directs or controls the immune response to the desired outcome. This ability to preferentially direct the immune system is a major breakthrough. Any diseases for which antigenic epitope sequences have been identified, such as infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, are potential candidates for this technology.

Those investors who wish to participate in this new generation of drugs/therapies would, we believe, be well served in the long-term by including CEL-SCI within the smallcap biotech section of a portfolio.

[[KERN]Codex]

Schaut Euch mal die Premarket Trades an, ob die AMIS es schaffen uns allein im vorbörslichen Handel vom Volumen zu toppen?

09:09 $ .98 2,200
09:08 $ .98 10,000
09:08 $ .98 5,000
09:06 $ .98 1,000
09:06 $ .9797 1,500
09:01 $ .95 2,000
08:59 $ .95 2,000
08:57 $ .94 500
08:57 $ .95 1,000
08:57 $ .90 1,000
08:57 $ .93 900
08:55 $ .9799 500
08:55 $ .98 1,000
08:54 $ .9799 1,500
08:39 $ .98 1,500
08:37 $ .9899 2,000
08:37 $ .98 1,000
08:34 $ .98 1,000
08:31 $ .95 1,500
08:24 $ .93 4,700
08:11 $ .93 700
08:11 $ .93 4,300
08:08 $ .93 4,000
08:05 $ .93 5,000
07:20 $ .97 100
07:17 $ .97 5,000
07:12 $ .93 300

http://www.nasdaq.com/aspxcontent/ExtendedTradingTrades.aspx…

[Sillak]

[posting]20.443.447 von Lanzalover am 01.03.06 15:06:05[/posting]Stell die Frage drüben im anderen Thread und Du bekommst eine Antwort

Gruß,
Sil

[[KERN]Codex]

[posting]20.444.192 von Sillak am 01.03.06 15:31:28[/posting]lanza hab Dir doch schon auf deine Frage in der BM geantwortet

hey sillak,

ich dachte du wolltest dich abmelden, hat w:0 gesiegt?

[[KERN]Codex]

CEL SCI ist kein Pennystock mehr



1 USD

[BronteSister]

[posting]20.444.532 von [KERN]Codex am 01.03.06 15:41:30[/posting]Sehe ich das richtig, daß wir bei einem Kurs von 1 USD in Deutschland unter pari liegen???
Aufklärung erbeten... Danke!

[Lanzalover]

[posting]20.445.834 von BronteSister am 01.03.06 16:24:56[/posting]einstiegschance?

ich warte aber erst den 3.3. ab . . .

[Sillak]

@Kerni!
Da war jemand, der wollte nicht auf mich verzichten. Obwohl...WO macht schon süchtig ;- )

Sil

[volkerg]

1,05 - + 18% ... da müssen wir aber doch ein bißchen nachlegen, gelle!?

[[KERN]Codex]

TH 1,05 USD = 0,88 EUR

[Lanzalover]

sage mal kerni, bist du eigentlich dieser germanlong unter den wütenden bullen in usa? und bist schon zwei jahre lang bei cel sci?

deswegen nun dein engagement? dann müsstest du den laden ja echt recht gut kennen . . .

[[KERN]Codex]

ne

[auric7]

was war den das vorher ?

[[KERN]Codex]

Schon 1,7 Mio Stücke umgesetzt, wenn wir Heute über 1 USD schließen würde das ein schönes Kaufsignal generieren, dass uns locker auf 1,2 USD bringen könnte

[[KERN]Codex]

Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets. Today`s upward activity on CEL-SCI Corp. (CVM), has grabbed the attention of our research team. Our goal is to create a community of international investors who consistently and effectively capitalize on the enormous gains that the small-cap Canadian and American exchanges offer.

Recently, Geert Kersten, CEO of CEL-SCI Corp. (CVM) updated the investment community in an all-new, exclusive interview with www.wallst.net . Topics covered in the interview include an overview of the Company and the markets it serves, recent press releases, current capitalization, upcoming strategic and financial milestones.

M.G will continue doing research on CEL-SCI Corp. (CVM) both short term and long term, and invite any shareholders to our site, where you can partake in communicating with other investors on the company.

Shares of CEL-SCI Corpare up over 15% on very large volume.

The information provided is brief and informative however becoming a member to our site will give you access to all the on-going information we come across on both of the above mentioned companies.

Investors seeking a resource to further their investment knowledge and be informed of exciting opportunity should take the easy step of becoming a member to www.marketgainer.com . Our service is free and at no time will we ever push any sort of annual subscription on you. The Market Gainer motto is "Our Success depends on Yours!"

This information has been brought to your attention by the research team at www.marketgainer.com and comes from an unbiased perspective. Although we are a boutique research firm, we have not made any investments in the above mentioned companies.

[[KERN]Codex]

0,85 USD sollten morgen auf Schlusskursbasis halten, das ist der stärkste Widerstand, wenn man aufs Volumen guckt, MACD und Slow Stoch auch sehr überverkauft

[Conjulio]

Hab ne Abstauberorder reingesetzt...

Sollte die (I love Konsi:laugh bedient werden, na dann sind wir doch fast alle wieder hier. Die ganze Molofamilie

[MikeSpezial]

[posting]20.456.002 von Conjulio am 02.03.06 02:25:39[/posting]Schade drum war wohl für BV keine Empfehlung wert, jetzt geht es erst mal wieder runter 0,6.

[[KERN]Codex]

Conjulio,

schön dass du auch dabei bist

[Conjulio]

Man sieht deutlich gerade eine kleine Verschnaufpause. Paar realisieren Gewinne. Ist auch gut so. Irgendeiner muss mir ja schliesslich seine shares geben

Zu Molo heute

[[KERN]Codex]

Ich habs doch angekündigt, dass Mologen erstmal konsolidiert, aber da du wie ich ja extrem long bist brauchst du Dir darum keinen Kopf zu machen

[Lanzalover]

hi!

lobt mich mal, das ich im molo-thread die stellung halte!

wie sieht`s hier aus?

habt ihr wegen einer super news betreffs cel-sci alle eurer kapital bei molo frei gemacht?

ne, war wohl wirklich eine sl-welle, was meint ihr?

ist das zweite mal, das ich sowas live mit bekomme und na ja, ist schon aufregend . . .

nun denn, mal sehen, was die sec morgen zu cel-sci`s filing-plan sagt

viel glück und erfolg euch allen!


mfg.

lanzalover


p.s.:

ansonsten immer noch gute nachkauf bzw. ek-preise bei mgn 12,45 / 12,35 aktuell

[[KERN]Codex]

lanza

es gibt leute die wollen deine aktien und die haben noch nicht fertig

[Lanzalover]

[posting]20.464.370 von [KERN]Codex am 02.03.06 14:47:53[/posting].

so so, was meinst du denn, wie weit die noch runterdrücken (können)?

[Conjulio]

Wir können hier gerne noch 2-3 Wochen in einer Range 0,60 -0,80 bleiben. Da hätte ich nichts gegen

[[KERN]Codex]

[posting]20.464.504 von Lanzalover am 02.03.06 14:54:00[/posting]11,5 EUR bestimmt

[buxte]

sehe vorbörslich 0,85/0,90

[[KERN]Codex]

p.s. kommt ganz drauf an ob bei 12 viele SLs liegen..

[[KERN]Codex]

buxte

letzter Kurs gestern war 0,90 USD - Heute auf AMEX und ARCAEX so gut wie kein vorbörslicher Handel!

Bin gespannt wie es Heute weiter geht, meine EMFP machen sich auch gut, die verkaufen diese Nanomasken, die haben auch gut konsolidiert und sind dann nochmal richtig angezogen

[[KERN]Codex]

FFM

Geld 0,75 25.000 St.
Brief 0,77 15.000 St.

[[KERN]Codex]

Feds Move to Speed Flu Vaccine Development
The Associated Press
Thursday, March 2, 2006; 12:01 PM


WASHINGTON -- Manufacturers may be able to speed to market new vaccines against seasonal and pandemic flu by following guidelines being published Thursday in draft form, federal regulators said.

The separate documents, prepared by the Food and Drug Administration, spell out what data the agency would require of manufacturers to demonstrate their vaccines are both safe and effective and before it can consider them for approval. The public has 90 days to comment on the guidelines before they are finalized.


Save & Share
Tag This Article


Saving options
1. Save to description:
Headline (required)

2. Save to notes (255 character max):
Blurb

3. Tag This Article

The goal is to accelerate the vaccine development and approval process when there is a shortage of vaccine to treat the seasonal flu or, more ominously, in the case of a flu pandemic.

In the case of a previously approved flu vaccine, manufacturers could tweak the vaccine for use against a pandemic flu strain without having to seek a new license from the FDA, according to the draft documents.

Additionally, for a manufacturer to receive accelerated approval, showing that a vaccine prompts a response from the body`s immune system could be considered sufficient evidence that it will guard against the flu and its sometimes deadly complications. The FDA also would ask that manufacturers carry out follow-up studies on the vaccines once they are in use _ even if its in the midst of a pandemic, according to the draft guidelines.

The guidelines follow the process the FDA used last year to quickly approve the new influenza vaccine Fluarix, the agency said.

Health officials worry that bird flu, as it spreads well beyond Asia, could mutate into a strain that can be easily passed from human to human, sparking a pandemic.

___

On the Net:

Food and Drug Administration

[[KERN]Codex]

Long-Term Sentiment: Strong Buy 03/02/06 10:18 am
Msg: 145208 of 145228

Its very important to all new cvm investors to listen closely.This board before the last few days was a total farce because certain ids (most of them suspected to be the same person) would come on here and blindly give you facts.My suggestion to you is please dont base your opinion on anyone except your broker or by calling the company or by doing your own research.The facts are that multikine which is the main drug had been submitted for phase 3 in canada and although there is no product this second when its time there will be.It has a definitive shelf life and there is no reason to have it laying around.Read the recent news on cvm about multikines success in its phase 2 trials.The leaps drug as you know is now patended that is also good.The bad is that one of the owners has sold many shares through the past year because hes 500 years old and is almost retired.Geert keersten who is the main man has bought heavily at times and is invested deeply work and stock wise.One of the main ids Soldhi has been on a hiatus while this major jump took place.He has posted as many as 30 times a day begging people to jump ship for whatever reasons although many suspect he is paid to do so.He is now back If you buy or sell because of a poster on yahoo you should be shot.This is no longer a stock to buy sell and buy in 1 day.The facts are in and this was a 6 dollar stock who like many went down and survived proving its viable.Dont go by me do your research call the company and good luck to all.Oh and by the way even if another company came up with a drug similar to multikine how would that hurt us?Last ichecked there are many drugs that do the same thing yet all companies thrive.Go buy something for your headache and tell me how many different drugs there are.

[biostratege]

Hallo an Alle
Sollte da nicht gestern eine Meldung rauskommen zwecks Delisting an der nasdag ?
Danke für eine Antwort

[Lanzalover]

[posting]20.508.089 von biostratege am 04.03.06 15:34:10[/posting]das würde ich auch gerne wissen . . .

[biostratege]

Hallo
Ich meinte natürlich AMEX
Gruß
PS: Gibt es noch nichts neues ?

[whyso]

(just a little bookmark, nothing more, nothing less...)

[[KERN]Codex]

Die Vogelgrippe wird in den USA erwartet

Wenn es soweit ist heisst es anschnallen und festhalten!

[[KERN]Codex]

Freie Bahn

[Lanzalover]

[posting]20.527.680 von [KERN]Codex am 06.03.06 00:44:57[/posting].

und das drohende de-listing, wie erwartet abgewandt?

[Kuhlake]

aus RAGING BULL


CEL-1000 successful against Avian (or bird) flu ???

Is the rumor right, that CEL-1000 can be used successful aginst Avian (or bird) flu???

Avian (or bird) flu is caused by influenza viruses that occur naturally among wild birds. The H5N1 variant is deadly to domestic fowl and can be transmitted from birds to humans. There is no human immunity and no vaccine is available.


CEL-SCI Signs Agreement With U.S. Government Institute for Testing of Drug Against Avian Flu Virus H5N1
Monday December 5, 7:00 am ET


VIENNA, Va., Dec. 5 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM - News) has signed a Cooperative Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health of the U.S. government, to test CEL-SCI`s patented anti- infective drug CEL-1000 against the avian (bird) flu virus H5N1 in animal models. The testing will be conducted to determine whether CEL-1000 could be used as a potential treatment and/or preventive agent against this virus.
ADVERTISEMENT


CEL-1000 has previously been shown to be protective in animal challenge studies against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria, and to enhance survival against cancer in animals. CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a broad-spectrum protection against infection in animal models. The innate immune system is generally accepted to be the first line of defense against infectious agents.

Geert Kersten, Chief Executive Officer of CEL-SCI said, "CEL-1000 has been successfully tested in a number of diseases with the support of the U.S. government. We hope that CEL-1000 can activate the immune system to successfully defeat the avian flu virus as it has done against other viruses."

CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host`s protective immune response.

The National Institutes of Health (NIH) -- The Nation`s Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company`s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation`s SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2004. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.




--------------------------------------------------------------------------------
Source: CEL-SCI Corporation



CEL-SCI Answers Questions Regarding Testing Agreement With NIH for Drug Against Avian Flu Virus H5N1
Tuesday December 6, 10:30 am ET


VIENNA, Va., Dec. 6 /PRNewswire-FirstCall/ -- On December 5, 2005, CEL-SCI CORPORATION (Amex: CVM - News) announced that it had signed a Cooperative Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health of the U.S. government, to test CEL-SCI`s patented anti-infective drug CEL-1000 against the avian (bird) flu virus H5N1 in animal models. The testing will be conducted to determine whether CEL-1000 could be used as a potential treatment and/or preventive agent against this virus.
The December 5th release has resulted in a number of questions from shareholders and the media. Since the questions are fairly uniform, CEL-SCI will attempt to answer them in this release.


1) Who will pay for the tests? The NIH will pay for the tests.
2) If the tests are successful, what will come next? That determination
will be made at that point in time and is not covered by the current
agreement.
3) Will supply of CEL-1000 delay the testing? No, CEL-SCI currently has
adequate amounts of CEL-1000 available for testing.
4) Is manufacturing of this product for the tests and/or potential sale of
the product a problem? No, we have CEL-1000 on hand to do the current
testing. CEL-1000 is produced for CEL-SCI by contract manufacturers.
There are several capable contract manufacturers who could produce and
formulate CEL-1000 into a drug product that meets all of the required
regulations.
5) You state that CEL-1000 is related to your L.E.A.P.S.(TM) technology
which requires a different antigen for each disease. Does CEL-1000
require the avian flu antigen? No, the great attraction of CEL-1000 in
this case is that it has previously been shown to protect animals
against viruses and unrelated diseases without a specific antigen. In
all of these tests, the same peptide was used. It is this lack of
specificity that makes CEL-1000 such an attractive potential therapy
against the changing avian flu virus.
6) How do you envision that your product could potentially be used against
the avian flu? We envision three potential applications. One, as a
preventive, since CEL-1000 was shown to be 100% protective in animal
challenge studies against viruses and unrelated diseases. Two, as a
treatment. Three, as an adjuvant to enhance the immune response to the
current avian flu vaccine being made. There is a clear need to reduce
the amount of antigen required for an immune response per person since
the current facilities cannot produce anywhere close to the amount of
vaccine required. The addition of an adjuvant to the vaccine should
allow for a larger number of vaccine doses with the same amount of
antigen which would expand substantially the number of persons who
could be vaccinated with a protective dose.
7) Why do you think that CEL-1000 might work against the avian flu virus?
CEL-1000 appears to activate innate (very early stage) and Th1 type
(cellular) immune responses to induce a broad-spectrum protection
against infection in animal models. The innate immune system is
generally accepted to be the first line of defense against infectious
agents. We believe that activating innate immunity might also help
against the avian flu virus.

CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host`s protective immune response.

The National Institutes of Health (NIH) -- The Nation`s Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company`s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation`s SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2004. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.




--------------------------------------------------------------------------------
Source: CEL-SCI Corporation

[Kuhlake]

aus RAGING BULL


CEL-1000 successful against Avian (or bird) flu ???

Is the rumor right, that CEL-1000 can be used successful aginst Avian (or bird) flu???

Avian (or bird) flu is caused by influenza viruses that occur naturally among wild birds. The H5N1 variant is deadly to domestic fowl and can be transmitted from birds to humans. There is no human immunity and no vaccine is available.


CEL-SCI Signs Agreement With U.S. Government Institute for Testing of Drug Against Avian Flu Virus H5N1
Monday December 5, 7:00 am ET


VIENNA, Va., Dec. 5 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM - News) has signed a Cooperative Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health of the U.S. government, to test CEL-SCI`s patented anti- infective drug CEL-1000 against the avian (bird) flu virus H5N1 in animal models. The testing will be conducted to determine whether CEL-1000 could be used as a potential treatment and/or preventive agent against this virus.
ADVERTISEMENT


CEL-1000 has previously been shown to be protective in animal challenge studies against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria, and to enhance survival against cancer in animals. CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a broad-spectrum protection against infection in animal models. The innate immune system is generally accepted to be the first line of defense against infectious agents.

Geert Kersten, Chief Executive Officer of CEL-SCI said, "CEL-1000 has been successfully tested in a number of diseases with the support of the U.S. government. We hope that CEL-1000 can activate the immune system to successfully defeat the avian flu virus as it has done against other viruses."

CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host`s protective immune response.

The National Institutes of Health (NIH) -- The Nation`s Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company`s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation`s SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2004. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.




--------------------------------------------------------------------------------
Source: CEL-SCI Corporation



CEL-SCI Answers Questions Regarding Testing Agreement With NIH for Drug Against Avian Flu Virus H5N1
Tuesday December 6, 10:30 am ET


VIENNA, Va., Dec. 6 /PRNewswire-FirstCall/ -- On December 5, 2005, CEL-SCI CORPORATION (Amex: CVM - News) announced that it had signed a Cooperative Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health of the U.S. government, to test CEL-SCI`s patented anti-infective drug CEL-1000 against the avian (bird) flu virus H5N1 in animal models. The testing will be conducted to determine whether CEL-1000 could be used as a potential treatment and/or preventive agent against this virus.
The December 5th release has resulted in a number of questions from shareholders and the media. Since the questions are fairly uniform, CEL-SCI will attempt to answer them in this release.


1) Who will pay for the tests? The NIH will pay for the tests.
2) If the tests are successful, what will come next? That determination
will be made at that point in time and is not covered by the current
agreement.
3) Will supply of CEL-1000 delay the testing? No, CEL-SCI currently has
adequate amounts of CEL-1000 available for testing.
4) Is manufacturing of this product for the tests and/or potential sale of
the product a problem? No, we have CEL-1000 on hand to do the current
testing. CEL-1000 is produced for CEL-SCI by contract manufacturers.
There are several capable contract manufacturers who could produce and
formulate CEL-1000 into a drug product that meets all of the required
regulations.
5) You state that CEL-1000 is related to your L.E.A.P.S.(TM) technology
which requires a different antigen for each disease. Does CEL-1000
require the avian flu antigen? No, the great attraction of CEL-1000 in
this case is that it has previously been shown to protect animals
against viruses and unrelated diseases without a specific antigen. In
all of these tests, the same peptide was used. It is this lack of
specificity that makes CEL-1000 such an attractive potential therapy
against the changing avian flu virus.
6) How do you envision that your product could potentially be used against
the avian flu? We envision three potential applications. One, as a
preventive, since CEL-1000 was shown to be 100% protective in animal
challenge studies against viruses and unrelated diseases. Two, as a
treatment. Three, as an adjuvant to enhance the immune response to the
current avian flu vaccine being made. There is a clear need to reduce
the amount of antigen required for an immune response per person since
the current facilities cannot produce anywhere close to the amount of
vaccine required. The addition of an adjuvant to the vaccine should
allow for a larger number of vaccine doses with the same amount of
antigen which would expand substantially the number of persons who
could be vaccinated with a protective dose.
7) Why do you think that CEL-1000 might work against the avian flu virus?
CEL-1000 appears to activate innate (very early stage) and Th1 type
(cellular) immune responses to induce a broad-spectrum protection
against infection in animal models. The innate immune system is
generally accepted to be the first line of defense against infectious
agents. We believe that activating innate immunity might also help
against the avian flu virus.

CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host`s protective immune response.

The National Institutes of Health (NIH) -- The Nation`s Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company`s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation`s SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2004. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.




--------------------------------------------------------------------------------
Source: CEL-SCI Corporation

[Kuhlake]

CEL-1000 successful against Avian (or bird) flu ???

Is the rumor right, that CEL-1000 can be used successful aginst Avian (or bird) flu???

Avian (or bird) flu is caused by influenza viruses that occur naturally among wild birds. The H5N1 variant is deadly to domestic fowl and can be transmitted from birds to humans. There is no human immunity and no vaccine is available.


CEL-SCI Signs Agreement With U.S. Government Institute for Testing of Drug Against Avian Flu Virus H5N1
Monday December 5, 7:00 am ET


VIENNA, Va., Dec. 5 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM - News) has signed a Cooperative Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health of the U.S. government, to test CEL-SCI`s patented anti- infective drug CEL-1000 against the avian (bird) flu virus H5N1 in animal models. The testing will be conducted to determine whether CEL-1000 could be used as a potential treatment and/or preventive agent against this virus.
ADVERTISEMENT


CEL-1000 has previously been shown to be protective in animal challenge studies against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria, and to enhance survival against cancer in animals. CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a broad-spectrum protection against infection in animal models. The innate immune system is generally accepted to be the first line of defense against infectious agents.

Geert Kersten, Chief Executive Officer of CEL-SCI said, "CEL-1000 has been successfully tested in a number of diseases with the support of the U.S. government. We hope that CEL-1000 can activate the immune system to successfully defeat the avian flu virus as it has done against other viruses."

CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host`s protective immune response.

The National Institutes of Health (NIH) -- The Nation`s Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company`s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation`s SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2004. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.




--------------------------------------------------------------------------------
Source: CEL-SCI Corporation



CEL-SCI Answers Questions Regarding Testing Agreement With NIH for Drug Against Avian Flu Virus H5N1
Tuesday December 6, 10:30 am ET


VIENNA, Va., Dec. 6 /PRNewswire-FirstCall/ -- On December 5, 2005, CEL-SCI CORPORATION (Amex: CVM - News) announced that it had signed a Cooperative Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health of the U.S. government, to test CEL-SCI`s patented anti-infective drug CEL-1000 against the avian (bird) flu virus H5N1 in animal models. The testing will be conducted to determine whether CEL-1000 could be used as a potential treatment and/or preventive agent against this virus.
The December 5th release has resulted in a number of questions from shareholders and the media. Since the questions are fairly uniform, CEL-SCI will attempt to answer them in this release.


1) Who will pay for the tests? The NIH will pay for the tests.
2) If the tests are successful, what will come next? That determination
will be made at that point in time and is not covered by the current
agreement.
3) Will supply of CEL-1000 delay the testing? No, CEL-SCI currently has
adequate amounts of CEL-1000 available for testing.
4) Is manufacturing of this product for the tests and/or potential sale of
the product a problem? No, we have CEL-1000 on hand to do the current
testing. CEL-1000 is produced for CEL-SCI by contract manufacturers.
There are several capable contract manufacturers who could produce and
formulate CEL-1000 into a drug product that meets all of the required
regulations.
5) You state that CEL-1000 is related to your L.E.A.P.S.(TM) technology
which requires a different antigen for each disease. Does CEL-1000
require the avian flu antigen? No, the great attraction of CEL-1000 in
this case is that it has previously been shown to protect animals
against viruses and unrelated diseases without a specific antigen. In
all of these tests, the same peptide was used. It is this lack of
specificity that makes CEL-1000 such an attractive potential therapy
against the changing avian flu virus.
6) How do you envision that your product could potentially be used against
the avian flu? We envision three potential applications. One, as a
preventive, since CEL-1000 was shown to be 100% protective in animal
challenge studies against viruses and unrelated diseases. Two, as a
treatment. Three, as an adjuvant to enhance the immune response to the
current avian flu vaccine being made. There is a clear need to reduce
the amount of antigen required for an immune response per person since
the current facilities cannot produce anywhere close to the amount of
vaccine required. The addition of an adjuvant to the vaccine should
allow for a larger number of vaccine doses with the same amount of
antigen which would expand substantially the number of persons who
could be vaccinated with a protective dose.
7) Why do you think that CEL-1000 might work against the avian flu virus?
CEL-1000 appears to activate innate (very early stage) and Th1 type
(cellular) immune responses to induce a broad-spectrum protection
against infection in animal models. The innate immune system is
generally accepted to be the first line of defense against infectious
agents. We believe that activating innate immunity might also help
against the avian flu virus.

CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host`s protective immune response.

The National Institutes of Health (NIH) -- The Nation`s Medical Research Agency -- includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company`s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation`s SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2004. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.




--------------------------------------------------------------------------------
Source: CEL-SCI Corporation

[Kuhlake]

[Maxholding]

Würd ja auch gern einsteigen, weil ich die Story spannend finde.
Verunsichert hat mich die Frage nach einem event. Delisting von der AMEX.
Was hat es damit auf sich????

[[KERN]Codex]

[posting]20.527.731 von Lanzalover am 06.03.06 01:06:10[/posting]Es wird kein Delisting geben.. außerdem hat CEL SCI bis APril Zeit

[Conjulio]

Hab nochmals nachgelegt. KZ 2€

[[KERN]Codex]

Kursziel ist 5 USD, nicht 2 USD

[Conjulio]

Also ich könnte mit 5 USD gut leben. Abwarten. Die FDA lässt grüssen.

[[KERN]Codex]

Hab am Samstag mit jemanden von der FDA in München über ISO Normen und Zulassungsverfahren gesprochen, ich denke lange werden wir auf die Zulassung nicht mehr warten

[Conjulio]

Solange die AMEX Geschichte gut geht, bleibt ja zu hoffen das aus Cel auch was werden kann.

Ich wiege mich in Zweckoptimismus!

[[KERN]Codex]

March 8, 2006 - 11:46 AM EST
Print Email Article Font Down Font Up Charts
close
Email this News Article
Your Name
Your Email
Friend`s Name
Friend`s Email
Receive Copy: yes

CVM 0.80 0.0301
Today 5d 1m 3m 1y 5y 10y

CEL-SCI Corporation Releases Letter to Shareholders

VIENNA, Va., March 08 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (Amex: CVM) to its shareholders:

Dear Fellow Shareholders:

CEL-SCI set out to create a cancer therapy that would work with the body, not against it; a cancer therapy that would help patients conquer their cancer with the first cancer treatment so that the cancer will not recur. We are pleased to report that recently analyzed follow-up data from the key Phase II clinical trial with our cancer drug Multikine(R) indicate that the drug had a substantial effect on the survival of the patients treated with it.

The long-term follow-up study of the head & neck cancer patients who received Multikine over 3 years ago showed a substantial improvement in both the survival rate and the local regional control of their tumors. The detailed results of this follow-up study are currently being prepared for publication in a scientific journal. These data, if confirmed in our planned Phase III clinical trial, would represent a huge step forward in the treatment of head & neck cancer patients.

The benefit of survival to the patient is obvious and survival is the gold standard of cancer drug development. Increased local regional control refers to the increased ability to delay the recurrence of the tumor in the head & neck area. If a drug can delay the recurrence of the tumor, the patient will have much improved life for the period during which there is no recurrence of disease. Clearly this is a meaningful benefit to the every-day life of a cancer patient, and in particular to a head & neck cancer patient, where local control often means preserving the ability to swallow, breathe and talk without assistance.

In our October 2005 letter to the shareholders we highlighted the three major contributions Multikine makes in fighting cancer and postulated that these contributions should lead to an increase in the success rate of the cancer treatment. We now have Phase II data that shows improved local regional control of the tumor as well as increased survival and we are therefore able to support our original hypothesis. Our next goal is to repeat these results in the planned Phase III clinical trial where the endpoints are the same as those that we measured in the follow-up study: local regional control of the tumor and survival.

The planned Phase III study already has been cleared for go-ahead by the Canadian regulators and CEL-SCI is currently awaiting word from the U.S. FDA. Since most of the head & neck cancer patients are outside of the U.S., we hope to conduct one worldwide Phase III study, including the countries of our Asian partner Orient EuroPharma, for drug approval.

We proceed on one simple assumption. If we can show clinical benefit by demonstrating increased survival or improved local regional control, or better yet, both, Multikine should end up being used as first-line therapy in head & neck cancer, 5% of all cancers worldwide. Ultimately it may even be useful in treating many other cancers as well. And, it cannot be stated often enough, Multikine has been essentially non-toxic. If we can achieve this, meeting worldwide demand for Multikine would likely become our challenge.

Let us again state the obvious: `If the cancer does not recur, you will have a much greater chance of survival.` That is our goal and the reason for adding Multikine to the standard first-line cancer therapy.

On a different note, we reported late last year that CEL-SCI had signed an agreement with the National Institute for Allergy and Infectious Diseases (NIAID), whereby NIAID agreed to test our CEL-1000 drug against the avian flu virus in animal models, which are very hard to come by. CEL-1000 is very interesting because it has protected against different viruses and parasites in animal models. Such broad based protection by CEL-1000 would be very helpful against the avian flu virus, as it undergoes constant mutation.

After discussions with avian flu virus experts we have decided that more research in the area of the avian flu virus infection and treatment with CEL- SCI products can and should be done. In conjunction with these experts we have developed a plan to test CEL-SCI products against the avian flu virus. The testing performed under this plan will be in addition to the testing of CEL-1000 that is currently being done by the NIAID. Some of what we are doing and plan to be doing will be obvious, but a lot of it focuses on areas that have not yet been highlighted in the popular press as areas in need of help. We will update you in the future on this program as it progresses.

We thank you for your support.

Sincerely,

Geert Kersten Maximilian de Clara
Chief Executive Officer President


When used in this report, the words `intends,` `believes,` `anticipated` and `expects` and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company`s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation`s SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2004. The Company undertakes no obligation to publicly release the result of any revision to these forward- looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE CEL-SCI Corporation

Source: PR Newswire (March 8, 2006 - 11:46 AM EST)

News by QuoteMedia
www.quotemedia.com

[zakk60]

Ich glaub er will nach Norden!

[[KERN]Codex]

Heute gehts erstmal rauf

[FrontSide]

[posting]20.588.775 von [KERN]Codex am 09.03.06 08:41:47[/posting]Dein Wort in Gottes Gehörgang

[[KERN]Codex]

Mein heutiges Kursziel ist mindesten 85$ CENT - die News von der FDA dürfte nicht mehr lange auf sich warten lassen

[Sillak]

@Kern
Hoffentlich...

Sil

[takefive]

Hi!

Noch jemand da?

Heute gehts noch nach Norden

Gruß takefive

[Sillak]

[posting]20.617.619 von takefive am 10.03.06 16:47:07[/posting]Bid/Ask
86.7 0.80 · 0.82 20.0

Sil

[Sillak]

Hauptsache die 0,8 halten!


9.4 0.81 · 0.82 3.5

0,81 RT

Die FDA kann ruhig ein bisschen Gas geben. Einen Fast Track Status wird es wohl nicht geben, zumindest zweifeln das unsere amerikanischen Freunde an!

Daumen drücken!

Gruß,
Sil

[[KERN]Codex]

RT 0,83$ Tageshoch

[gerl28]

Hallo,
bin seit gestern auch dabei
Allen viel Glück(obwohl wir es nicht unbedingt benötigen)!

MfG
gerl

[volkerg]

Detailed Quote Snapshot 03/10/2006 04:07 PM
Last:
0.83

cvm - CEL-SCI CORP
Change:
+0.02

% Change:
+2.47%

High:
0.84

Low:
0.78

Volume:
322,200


Der SK drüben dürfte für 0,7x am Montag locker ausreichen...

[[KERN]Codex]

0,75 EUR könnten wir bestimmt sehen, ich sach ja alles unter 1 USD ist sowieso ein Schnäppchen

[[KERN]Codex]

Press Release Source: CEL-SCI Corporation


CEL-SCI Corporation Releases Letter to Shareholders
Wednesday March 8, 11:46 am ET


VIENNA, Va., March 08 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI CORPORATION (Amex: CVM - News) to its shareholders:

Dear Fellow Shareholders:

CEL-SCI set out to create a cancer therapy that would work with the body, not against it; a cancer therapy that would help patients conquer their cancer with the first cancer treatment so that the cancer will not recur. We are pleased to report that recently analyzed follow-up data from the key Phase II clinical trial with our cancer drug Multikine® indicate that the drug had a substantial effect on the survival of the patients treated with it.

The long-term follow-up study of the head & neck cancer patients who received Multikine over 3 years ago showed a substantial improvement in both the survival rate and the local regional control of their tumors. The detailed results of this follow-up study are currently being prepared for publication in a scientific journal. These data, if confirmed in our planned Phase III clinical trial, would represent a huge step forward in the treatment of head & neck cancer patients.

The benefit of survival to the patient is obvious and survival is the gold standard of cancer drug development. Increased local regional control refers to the increased ability to delay the recurrence of the tumor in the head & neck area. If a drug can delay the recurrence of the tumor, the patient will have much improved life for the period during which there is no recurrence of disease. Clearly this is a meaningful benefit to the every-day life of a cancer patient, and in particular to a head & neck cancer patient, where local control often means preserving the ability to swallow, breathe and talk without assistance.

In our October 2005 letter to the shareholders we highlighted the three major contributions Multikine makes in fighting cancer and postulated that these contributions should lead to an increase in the success rate of the cancer treatment. We now have Phase II data that shows improved local regional control of the tumor as well as increased survival and we are therefore able to support our original hypothesis. Our next goal is to repeat these results in the planned Phase III clinical trial where the endpoints are the same as those that we measured in the follow-up study: local regional control of the tumor and survival.

The planned Phase III study already has been cleared for go-ahead by the Canadian regulators and CEL-SCI is currently awaiting word from the U.S. FDA. Since most of the head & neck cancer patients are outside of the U.S., we hope to conduct one worldwide Phase III study, including the countries of our Asian partner Orient EuroPharma, for drug approval.

We proceed on one simple assumption. If we can show clinical benefit by demonstrating increased survival or improved local regional control, or better yet, both, Multikine should end up being used as first-line therapy in head & neck cancer, 5% of all cancers worldwide. Ultimately it may even be useful in treating many other cancers as well. And, it cannot be stated often enough, Multikine has been essentially non-toxic. If we can achieve this, meeting worldwide demand for Multikine would likely become our challenge.

Let us again state the obvious: "If the cancer does not recur, you will have a much greater chance of survival." That is our goal and the reason for adding Multikine to the standard first-line cancer therapy.

On a different note, we reported late last year that CEL-SCI had signed an agreement with the National Institute for Allergy and Infectious Diseases (NIAID), whereby NIAID agreed to test our CEL-1000 drug against the avian flu virus in animal models, which are very hard to come by. CEL-1000 is very interesting because it has protected against different viruses and parasites in animal models. Such broad based protection by CEL-1000 would be very helpful against the avian flu virus, as it undergoes constant mutation.

After discussions with avian flu virus experts we have decided that more research in the area of the avian flu virus infection and treatment with CEL- SCI products can and should be done. In conjunction with these experts we have developed a plan to test CEL-SCI products against the avian flu virus. The testing performed under this plan will be in addition to the testing of CEL-1000 that is currently being done by the NIAID. Some of what we are doing and plan to be doing will be obvious, but a lot of it focuses on areas that have not yet been highlighted in the popular press as areas in need of help. We will update you in the future on this program as it progresses.


Strong Buy

[BronteSister]

gibts hier noch Leben in diesem Thread?
Kann jemand sagen, wie lange die Vorlauf/Approvel-Zeiten bei der FDA liegen?
Gibt es irgendwo im Internet so eine Art Roadmap von Cel-Sci?

[Moz68]

CEL fällt in Frankfurt um 10% auf 0,60 Cent, gibt`s etwa was neues bzgl. Delistung?

[BronteSister]

ich denke nicht, konnte keine News finden
wie wird denn die Eröffnung in USA ausfallen? Hat jemand da vorbörsliche Quotes?
@Kern, untere Unterstützung sollte erreicht sein, oder?
0,60€ ~ 0,74USCent

[Sillak]

[posting]20.676.455 von Moz68 am 14.03.06 14:43:00[/posting]Hallo Moz68!
Die Lage ist wegen...

The plan indicated that it would file the 10-K by March 20, 2006.

...auf jeden Fall in der entscheidenden Phase. Leider ist CEL nicht verpflichtet uns mitzuteilen, ob sie es jetzt schaffen werden oder nicht...
Es gibt also jetzt zwei Möglichkeiten. Anrufen oder abwarten...aber Daumen drüken sollte man allemal

Gruß,
Sil

[Sillak]

Kleiner Nachtrag...

Könnte sein, dass CEL die Deadline einhält

Gruß,
Sil

[volkerg]

Moin! Kann mir evtl. einer das gestrige Plus von 13% erklären? Gibts was Neues?
Bin grad auf Dienstreise und hab kaum Zeit, selbst zu recherchieren... - merci!

[Sillak]

[posting]20.722.901 von volkerg am 16.03.06 08:29:03[/posting]Moin volker!
War nur mit sehr wenigen Shares gestiegen.
Im US Board macht man bereits vergleiche mit einer anderen Firma, die auch nicht an der Amex ist und trotzdem steigt und steigt. Die PIII ist eben wichtig...
Trotzdem wäre es ja ganz nett, wenn sie bleiben würden.

CEL hörte sich am Telefon bzgl. des Filings ziemlich zuversichtlich an...

Daumen drücken...

Gruß,
Sil

[[KERN]Codex]

Ich sags Euch -> Strong Buy, 100% auf Sicht von einem Quartal sind mehr als möglich

[volkerg]

In den USA schon netter Anstieg auf 0,78 -> 0,65 €

[Silberpfeil1]

Aktuelle Mitteilung:

CEL-SCI REQUESTS ADDITIONAL TIME TO FILE 10-K





VIENNA, VA, MARCH 17, 2006 -- CEL-SCI CORPORATION (AMEX: CVM) has asked the American Stock Exchange (“AMEX”) for additional time to file its 10-K for the year ending September 30, 2005. CEL-SCI had previously indicated that it planned to file the 10-K by March 20, 2006 and the Company’s quarterly report for the period ending December 31, 2005 by April 6, 2006. The reasons for not being able to file the 10-K on time are described in the Company’s press release dated January 18, 2006.



CEL-SCI believes that, barring unforeseen circumstances, it will be able to file the 10-K for the year ending September 30, 2005 during the week of March 27, 2006. If that is the case, CEL-SCI still plans to file its quarterly report (10-Q) for the period ending December 31, 2005 by April 6, 2006.



Geert Kersten, Chief Executive of CEL-SCI, said, “We have been working with three accounting firms to finalize these financial statements by March 20, 2006, but the issues involving FAS 133 and EITF 00-19 are extremely complex and time consuming. Our primary goal has to be that we get it right and, despite a massive effort by all parties involved, this delay for the 10-K is simply unavoidable.”



CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.



When used in this report, the words "intends," “plans,” "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

[[KERN]Codex]

[[KERN]Codex]

[[KERN]Codex]

Antwort auf Beitrag Nr.: 20.995.651 von [KERN]Codex am 29.03.06 17:59:29

Geld
0,57

Brief
0,60

Zeit
29.03. 19:18

Geld Stk.
7.700

Brief Stk.
2.000

In Stuttgart gibts noch welche für 60 CENT!

[[KERN]Codex]

Heute ist die richtige Zeit zu kaufen, könnte die nächsten Tage super weiterlaufen

[[KERN]Codex]

Vorbörslich rauf auf 0,89 USD +8,54%

[[KERN]Codex]

Und in FFM und Stuttgart gibts noch 8k 5% unter Pari

[[KERN]Codex]

04.04.2006 15:49
CEL-SCI Files Patent for Prevention/Treatment of Bird (Avian) Flu

VIENNA, Va., April 4 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Nachrichten) announces that it has filed a provisional U.S. patent application covering its drug CEL-1000 for the prevention/treatment of bird flu and/or as an adjuvant to be included in a bird flu vaccine.

Geert Kersten, Chief Executive Officer of CEL-SCI said, "By filing this patent in the U.S., we are preserving our rights to file patents on this invention world-wide."

CEL-1000, when used as a single adjuvant (enhancer of a vaccine) or in combination with other adjuvants, potentiates Th1 (cellular) and innate (earliest stage) immune responses and protects animals from viral and parasitic challenge. CEL-1000 provides antigen-independent (i.e., non-disease specific) and broad-spectrum protection upon challenge with the disease causing agent(s), which is important against the bird flu virus since it exhibits a high mutation rate.

CEL-1000, is a patented defined amino acid sequence derived from the beta chain of human MHC-II, which itself is a modified version of a human immune- based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective immune response. It is a defined peptide, which binds to the CD4 and/or likely a related molecule LAG-3 on dendritic cells, macrophages and T cells, thereby promoting the release of cytokines responsible for activating a protective Th1 immune response (e.g., IL-12 and upon challenge IFN-gamma).

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

When used in this report, the words "intends," "plans," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


WIR HABEN DEN DOLLAR GEKNACKT

[[KERN]Codex]

1,24 USD

[[KERN]Codex]

Eben sagenhafte 1,40 USD - jetzt wieder 1,33 USD.. hängt mit folgenden News zusammen:


Cel-Sci flies on Avian flu vaccine
Tuesday April 4, 1:36 pm ET


Stock in Northern Virginia biotechnology company Cel-Sci rallied as much as 21 percent Tuesday, after the company filed a patent application for an Avian flu vaccine.
The Vienna-based company says the application covers its drug CEL-1000 for both the prevention and treatment of bird flu.


The drug provides broad-spectrum protection, which Cel-Sci says is important against the bird flu virus because the virus exhibits a high mutation rate.

In December, Cel-Sci signed an agreement with the National Institutes of Health to test the vaccine as a potential Avian flu vaccine in clinical trials with animals. The drug has shown positive results in animal tests against herpes simplex virus, encephalitis and malaria.

Cel-Sci (AMEX: CVM - News) is one of several area biotechs developing an Avian flu vaccine. Gaithersburg-based MedImmune (NASDAQ: MEDI - News) is also working with NIH to produce and test vaccines against potential pandemic flu strains.

Novavax (NASDAQ: NVAX - News) is advancing clinical trials of its experimental bird flu vaccine. The company is now based in Philadelphia, but maintains a research facility in Rockville.

Cel-Sci shares rose 18 cents to $1 per share in Tuesday trading. Its stock has doubled since the beginning of the year.

Published April 4, 2006 by the Washington Business Journal

[rajiva35]

was für ein lauf heute

[rajiva35]

Antwort auf Beitrag Nr.: 21.075.858 von rajiva35 am 04.04.06 21:09:28

RT 1,64US$

[nort.]

[rajiva35]

Antwort auf Beitrag Nr.: 21.077.098 von nort. am 04.04.06 22:15:27

was meint ihr, geht da noch mehr?
Die Quartalszahlen sollen ja auch in der ersten Aprilwoche kommen

[[KERN]Codex]

Jo da geht noch mehr eindeutig,

die sind total unterbewertet im Peer Group Vergleich


Flu pandemic would hit insurers hard, trade group says
Jerry W. Jackson

April 4, 2006 2:45 PM

The Orlando Sentinel

ORLANDO, Fla. - In a typical year, 36,000 Americans die from common influenza strains. U.S. life-insurance companies incorporate those projected deaths into their grim calculations to remain profitable.

But if the bird flu starts spreading person to person and sparks a global pandemic, as some experts fear, deaths would soar. And if it gets as bad as the 1918 killer flu, it would cost insurance companies a staggering $133 billion in U.S. claims alone, according to estimates by the Insurance Information Institute, a trade group.

''I don't want to be alarmist, but it could be worse than that,'' Steven Weisbart, chief economist for the New York-based institute, said in an interview Tuesday.

The death rate for the 1918 Spanish flu was not as high as the death rate among the small number of humans who have already contracted bird flu, he said, so modeling on the 1918 experience might understate the insurance industry's costs.

Many experts say the bird flu's death rate almost certainly would drop from its apparent rate of about 50 percent if the disease begins spreading from person to person, but no one knows what the rate would eventually prove to be.

Bird flu, in fact, may never become transmissible among humans - most strains of avian influenza never do - but Weisbart said insurance companies should plan for a pandemic just as other businesses and the medical community are doing.

There appear to be many valid reasons why international health experts are sounding alarms, he said, over the current bird flu - type A, H5N1 strain. But life insurers, who are vulnerable to economic hits from catastrophes of all types, do not seem to be buying more reinsurance or adding to their reserves because of the flu, which has spread from Southeast Asia to Europe in recent months, Weisbart said.

''There's no evidence it's going up,'' Weisbart said of the companies' reinsurance levels and loss reserves. ''From what I can tell, their attention has been on the business-operation side.''

Insurance companies, like most large businesses pondering the awful consequences of a pandemic, which many experts says is statistically overdue, are taking steps to stay in business with a smaller staff.

Many workers will fall ill or remain home to avoid exposure. ''They will need someone to keep paying (death) claims,'' Weisbart said of insurance companies.

New York Life Insurance Co. spokesman Jorge Vargas said Tuesday the New York-based company and its international operations are preparing for a pandemic. The company is encouraging New York Life operations to make business-continuity decisions at the local level, with local authorities, wherever they are in the world, Vargas said.

It's important for the company to try to do everything possible to maintain operations in the midst of a major flu outbreak, he said, particularly in communicating ''with (our) customers, and (insurance) agents and employees.''

But Vargas said New York Life is not boosting its reinsurance, which insurers can buy to buffer against losses that they may be unable to handle. Nor is it adding to reserves.

''We are able to pay all claims, if this happens,'' Vargas said of a flu pandemic. ''We don't envision any change at this time. We don't envision any modification in our underwriting or reinsurance (levels), as of today.''

Industry experts say reinsurance specifically for bird flu is virtually non-existent. And reinsurance for all perils is expensive. But big reinsurers, looking at the statistics and odds, are beefing up their own reserves in case of a bird-flu pandemic.

Weisbart said that, if the flu kills at the more moderate rate of the 1957 and 1968 outbreaks, it would cost insurers an extra $31 billion. In any case, he said, insurers would take a financial hit, many would be forced into the capital markets, and weak ones would fail.

There's good news for the industry in the report: If a pandemic occurs and follows the pattern of the 1918 outbreak, life insurers would sell a whole lot of new policies once the deaths subside.

---

(c) 2006, The Orlando Sentinel (Fla.).

Visit the Sentinel on the World Wide Web at http://www.orlandosentinel.com/.

Distributed by Knight Ridder/Tribune Information Services.

AP-NY-04-04-06 1743EDT

[Lanzalover]

Antwort auf Beitrag Nr.: 21.078.358 von [KERN]Codex am 05.04.06 00:02:53

hi kern!

hätte mir ich vorgestern bloß mehr zeit genommen,
deinen tipp nachzugehen und mir den chart etc. von cel sci angesehen hätte . . !

tja, kann man nichts machen, herzlichen glückwunsch euch allen!


mfg.

lanzalover

p.s.:

was meinst du, mit welchem limit hätte morgen in der eröffnungsauktion noch chance reinzukommen?

[rajiva35]

Antwort auf Beitrag Nr.: 21.078.358 von [KERN]Codex am 05.04.06 00:02:53

Hi Kern,

schön
Ich hab zwar heute bei 50% meiner Papiere schon gewinne realisiert, aber der Rest bleibt erst mal drin

Viele Grüße
Rajiva35

[Topscorer]

Hallo zusammen,


vielen Dank an Kerni für den Klasse Tip.
Hab vorgestern ein paar Molo´s verkauft und bin gestern Mittag
mit dem Geld massiv in CEL Sci rein.

Hat sich gelohnt !!!

[Cors]

Sind 1,5 heute drin ?
Was denkt ihr ?

[gerl28]

Hi,
durch H5N1 rückt CVM ins Rampenlicht,aber durch die Zulassung
für Phase-III geht die Post erst richtig ab!!!
Bis dahin werde ich nicht eine einzige Aktie verkaufen

MfG
gerl

[rajiva35]

momentan relativ starke korrektur, bin am überlegen wieder nachzukaufen

was meint ihr, geht es noch weiter runter?

[[KERN]Codex]

So bin auch bereit um Nachzukaufen

[gerl28]

Ich weiss es nicht!
Vielleicht kühlt es die Tage etwas ab,aber auf der anderen Seite
kann auch jeder Zeit die nächste Hammernews reinschneien
Wie wärs mit Teilkauf?

MfG
gerl

[rajiva35]

Antwort auf Beitrag Nr.: 21.089.603 von gerl28 am 05.04.06 17:02:15

diese Woche sollen ja auch die Quartalszahlen kommen, ich schau mir das noch ein bisschen an

Scheint sich jetzt bei 1,30 einzupendeln.

[Tscholle]

auch wenn es schwer fällt: ABWARTEN !!!
--> long = winner !!!

[rajiva35]

heute gehts wieder kräftig nach oben

[[KERN]Codex]

CVM beweist Stärke

[[KERN]Codex]

Fears of a widespread outbreak of bird flu in Britain receded as an infected swan found in Scotland remained the only confirmed case of the deadly H5N1 strain out of some 1,100 birds examined since the end of February. Nevertheless, government health officials said they had made plans for the mass closure of schools in Scotland, amid warnings that 100,000 children might die if the bird flu virus mutates into a human pandemic.

The chief medical officer for England and Wales, Sir Liam Donaldson, said that shutting schools could reduce by half the number of pupils who would be killed if the bird flu virus mutates into a form that is transferable between humans. Advert for The Scotsman Digital Archive

"Until the pandemic virus emerges, we cannot know for certain which groups would be most vulnerable," Donaldson wrote. "If all age groups were affected equally, and the virus was particularly severe, the excess deaths in school-age children could be as high as 100,000. This would mean that potentially 50,000 deaths might be prevented by school closures."

Scottish newspapers reported that off-duty firemen and retired truck drivers might be pressed into service to ensure deliveries of essential food supplies in the event of a bird flu pandemic.

There is no evidence that the H5N1 strain of bird flu can pass between people. But there are fears it might mutate or mix with human flu viruses to create a new virus.

Residents of Cellardyke, where the infected swan was found, were being closely monitored. Hospitals and doctors have been placed on alert and are prepared to quarantine patients suspected of suffering from the early stages of the virus. Residents who came into close contact with the dead swan have been advised to check their temperature twice a day and report to a doctor at the first signs of coughing, sore throat or fever.

Doctors are also to visit all residents who went near the swan to take blood samples to ensure no one is carrying the virus without suffering any symptoms.

Meanwhile, the UN's chief coordinator on bird flu, David Nabarro, said the death of the Scottish swan suggested other birds were carrying the viurs in Britain.

"The one swan is a good indicator there will be other species, like ducks and geese, that are flying around carrying H5N1, excreting it in their faeces and therefore also capable of getting infection into domestic poultry and into other species," Nabarro said.

[[KERN]Codex]

Cel Sci Cp CEL-1000 Peptide Shows Adjuvant Activity with Malaria Vaccines

VIENNA, Va., April 19 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (AMEX:CVM) announced today that its CEL-1000 peptide showed adjuvant activity when used with a peptide based malaria vaccine and a DNA based malaria vaccine in animal challenge studies as part of a Cooperative Research arrangement with the Naval Medical Research Center, Silver Spring, MD. In both cases the one time addition of the patent protected CEL-1000 to the vaccines resulted in significant increases in the protection of the animals.

This new data indicates that CEL-1000 has protective activity in various animal models. These results are very important because CEL-SCI is planning to develop CEL-1000 as a potential addition to the different bird flu vaccines currently under development by the pharmaceutical and biopharmaceutical industry. It recently became very apparent that there is a great need for an adjuvant for these vaccines. Adjuvants are designed to improve the effectiveness of vaccines.

On March 30, 2006 the New England Journal of Medicine ("NEJM") published the results of the first human testing of a H5N1 bird (avian) flu vaccine. It showed that the vaccine, which was produced by the pharmaceutical giant Sanofi-Aventis, sparked a protective immune response in a disappointingly small percentage of vaccine recipients -- 54 percent of those who received two shots, 28 days apart, of the highest dose tested. This dose was twelve times higher than that needed for protection by the "normal" human flu vaccine where protection rates are generally in the 80-90% range.

This study identified 3 problems with this bird flu vaccine: 1) Each person requires so much vaccine that the government will not be able to build up the necessary stockpiles to protect the general population from the bird flu. 2) Only about half the people respond with the desired immune responses. 3) It takes a long time to produce an immune response during which time the person is not protected.

Dr. Daniel Zimmerman, Senior V.P of Research, Cellular Immunity, at CEL- SCI Corporation said, "This new data confirms our belief that CEL-1000 could be an important addition to the bird flu vaccines. That is why CEL-SCI is in contact with all of the major bird flu vaccine developers to test CEL-1000 with their vaccines."

In December 2005, CEL-SCI signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), whereby NIAID agreed to test CEL- 1000 as a possible vaccine or treatment against bird flu virus H5N1 in its animal models of the disease.

CEL-1000, when used as a single adjuvant (enhancer of a vaccine) or in combination with other adjuvants, potentiates Th1 (cellular) and innate (earliest stage) immune responses and protects animals from viral and parasitic challenge. Upon challenge with the disease causing agent(s), CEL- 1000 provides antigen-independent (i.e., non-disease specific) and broad- spectrum protection, which is important against the bird flu virus since it exhibits a high mutation rate.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

When used in this report, the words "intends," "plans," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

DATASOURCE: CEL-SCI Corporation


CONTACT: Stockholders Contact: Gavin de Windt of CEL-SCI Corporation,

[phone]; or Institutional Investors, Brokers & Analysts Contact:

Michael Lucci of Lucci Financial Group LLC, [phone], for CEL-SCI

Corporation


Web site: http://www.cel-sci.com/

[[KERN]Codex]

Antwort auf Beitrag Nr.: 21.138.476 von [KERN]Codex am 09.04.06 23:23:19

Wer noch nicht drin ist, rein daaa

[nort.]

schon gesehen?

http://edgar.brand.edgar-online.com/default.aspx?sym=cvm

[[KERN]Codex]

Cel-Sci Up on Vaccine Booster Tests
Wednesday April 19, 3:09 pm ET
Cel-Sci Shares Rise on Study Showing Compound Improves Malaria Vaccine


VIENNA, Va. (AP) -- Shares of Cel-Sci Corp. rose Wednesday after the small biotech company said one of its experimental compounds improved the effectiveness of a malaria vaccine in animals.
Cel-Sci shares rose 5 cents, or nearly 4 percent, to $1.32 in afternoon trading on the American Stock Exchange. Over the past 52 weeks, shares have traded between 44 cents to $1.78, and have nearly tripled in value since the beginning of the year.

In studies with Naval Medical Research Center, the company said the vaccine-enhancing CEL-1000 peptide increased protection against malaria in various animals tested.

The company said CEL-1000 could also work with various bird flu vaccines now being developed to make those medicines more effective against the virus responsible for the disease.

Cel-Sci is also working on immune system treatments for cancer and infectious diseases.

[[KERN]Codex]

[[KERN]Codex]

AP
Cel-Sci, Navy Extend Drug Study
Thursday April 20, 11:35 am ET
Cel-Sci, U.S. Navy to Extend Co-Evaluation of Malaria Drug


VIENNA, Va. (AP) -- Cel-Sci Corp. said Thursday it extended its partnership with the Naval Medical Research Center to jointly evaluate malaria drug CEL-1000.
The drug is still in preclinical trials, but the company said it shows promise to improve the effectiveness of vaccines for malaria and other diseases, including avian flu.

The World Health Organization said malaria affects about 350-500 million people a year and is responsible for about a million deaths annually. Most infections and deaths occur in sub-Saharan Africa.

Shares of Cel-Sci, which have traded between 44 cents and $1.78 over the last year, rose 4 cents, or 3 percent, to $1.35 in morning trading on the American Stock Exchange.

[nort.]

Symbol: CVM
Last Trade: 1.45 4:50PM ET
After Hours Change: Up 0.12 (9.02%)
Today's Change: Up 0.14 (10.69%)
Bid: 1.35
Ask: 1.45

[[KERN]Codex]

MIDAS!

[[KERN]Codex]

Form 10-K for CEL SCI CORP


--------------------------------------------------------------------------------

25-Apr-2006

Annual Report



ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with the Consolidated Financial Statements and Notes thereto appearing elsewhere in this report. See "Risk Factors". As discussed in Note 2 to the consolidated financial statements, the Company's financial statements have been restated. The accompanying management's discussion and analysis gives effect to that restatement.

OVERVIEW

CEL-SCI's most advanced product, Multikine, manufactured using the Company's proprietary cell culture technologies, is being developed for the treatment of cancer. Multikine is designed to target the tumor micro-metastases that are mostly responsible for treatment failure. The basic idea of Multikine is to make current cancer treatments more successful. Phase II data indicated that Multikine treatment resulted in a substantial increase in the survival of patients. The lead indication is advanced primary head & neck cancer (500,000 new cases per annum). Since Multikine is not tumor specific, it may also be applicable in many other solid tumors.

CEL-SCI also owns a pre-clinical technology called L.E.A.P.S. (Ligand Epitope Antigen Presentation System). The lead product derived from this technology is the CEL-1000 peptide which has shown protection in animals against herpes, malaria and cancer. With the help of government grants, NIAID and US Army and US Navy collaborations, CEL-1000 is now being tested against avian flu, viral encephalitis, West Nile Virus, SARS, Vaccinia, Smallpox, herpes, malaria and other agents. If the bio-terrorism tests are successful, CEL-SCI is likely to push CEL-1000 for potential bio-terrorism disease indications to gain accelerated approval.

Since inception, CEL-SCI has financed its operations through the issuance of equity securities, convertible notes, loans and certain research grants. CEL-SCI's expenses will likely exceed its revenues as it continues the development of Multikine and brings other drug candidates into clinical trials. Until such time as CEL-SCI becomes profitable, any or all of these financing vehicles or others may be utilized to assist CEL-SCI's capital requirements.

Results of Operations

Fiscal 2005

"Grant revenues and other" decreased by $55,554 during the year ended September 30, 2005, compared to 2004. This was due to the winding down of the work funded by the grants in 2005. CEL-SCI is continuing to apply for grants to support its work.

During the year ended September 30, 2005, research and development expenses increased by $288,099. The increase in research and development expense was due largely to an increase in work related to CEL-SCI's Phase III application for Multikine.

During the year ended September 30, 2005, general and administrative expenses decreased by $379,736. The decrease was mostly due to a decrease in public relations and corporate presentation expenses, filing fees, travel expenses, accounting fees and legal fees, as CEL-SCI's efforts were primarily focused on the submission of the Phase III clinical trial application for Multikine.

The Company received $625,472 in settlement of a lawsuit in which the Company was not a party. The litigation involved a shareholder and three former investors in CEL-SCI. The lawsuit sought to recover short-swing profits allegedly obtained by the defendants, their investment advisor and the investment advisor's principal acting together as a group in trading CEL-SCI securities.

Interest income during the year ended September 30, 2005 increased by $843 as a result of higher balances in interest bearing accounts during the year. Interest expense decreased to zero as a result of the conversion of the remaining convertible debt in October 2003. Interest expense for the year ended September 30, 2004 is primarily for interest related to the convertible debt payable to Cambrex Biosciences, Inc. and Covance AG.

Gain on derivative instruments for the year ended September 30, 2005 decreased by $811,632 due to a decrease in the number of derivative instruments outstanding during the year as a result of expiration of certain agreements or reclassifications of certain instruments to equity.

Fiscal 2004

Grant revenue and other during fiscal year 2004 remained at approximately the same level as fiscal year 2003 as work continued on the four grants received during the fiscal year 2003. Interest income also remained approximately at the same level.

Research and development expense increased by approximately $26,000 as the Company's research and development costs on L.E.A.P.S. increased during fiscal 2004.

General and administrative expenses increased by approximately $23,000 this year. The Company's cost reduction program continues. This reduction was substantially offset by an increase in audit and audit-related fees and an increase in filing and registration fees.

CEL-SCI recognized a gain of $1,174,660 on derivative instruments during fiscal year 2004 compared to a loss of $2,319,005 for the year ended September 30, 2003. This was due to primarily to a decrease in the trading price of CEL-SCI's common stock which is a significant component of fair value of the Company's derivative instruments. Also, during fiscal year 2004, several derivative instruments met the criteria for equity classification after which they were no longer marked to market.

Other costs of financing decreased by $270,664 during fiscal year 2004 since the Company did not enter into an equity line of credit financing arrangement during the year.


Research and Development Expenses

During the five years ended September 30, 2005 CEL-SCI's research and
development efforts involved Multikine, L.E.A.P.S. and an AIDS vaccine. The
table below shows the research and development expenses associated with each
project during this five-year period.

2005 2004 2003 2002 2001
---- ---- ---- ---- ----
MULTIKINE $1,911,615 $1,539,454 $1,653,904 $4,405,678 $7,365,305
L.E.A.P.S. 318,114 402,176 261,597 244,769 280,766
AIDS Vaccine -- -- -- 43,462 94,642
Other -- -- -- 6,000 21,500
---------- ---------- ---------- ---------- ----------

TOTAL $2,229,729 $1,941,630 $1,915,501 $4,699,909 $7,762,213
========== ========== ========== ========== ==========




CEL-SCI believes that it has compiled sufficient data and clinical information to justify a Phase III clinical trial which would be designed to prove the clinical benefit from Multikine as an addition to established anti-cancer therapies. In 2005, CEL-SCI submitted a protocol to the FDA and the Canadian regulatory agency, the Biologics and Genetic Therapies Directorate for Phase III clinical trials. CEL-SCI is unable to estimate the future costs of research and clinical trials involving Multikine since CEL-SCI has not yet finalized the protocol with the FDA. Until the scope of these trials is known, CEL-SCI will not be able to price any future trials.

As explained in Item 1 of this report, as of February 28, 2006, CEL-SCI was involved in a number of pre-clinical studies with respect to its L.E.A.P.S. technology. As with Multikine, CEL-SCI does not know what obstacles it will encounter in future pre-clinical and clinical studies involving its L.E.A.P.S. technology. Consequently, CEL-SCI cannot predict with any certainty the funds required for future research and clinical trials and the timing of future research and development projects.

Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of CEL-SCI's clinical trials and research programs are primarily based upon the amount of capital available to CEL-SCI and the extent to which CEL-SCI has received regulatory approvals for clinical trials. The inability of CEL-SCI to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent CEL-SCI from completing the studies and research required to obtain regulatory approval for any products which CEL-SCI is developing. Without regulatory approval, CEL-SCI will be unable to sell any of its products.

Since all of CEL-SCI's projects are under development, CEL-SCI cannot predict when it will be able to generate any revenue from the sale of any of its products.

CEL-SCI discontinued its research efforts relating to the AIDS vaccine due to a lack of government funding in 2000.

Liquidity and Capital Resources

CEL-SCI has had only limited revenues from operations since its inception in March l983. CEL-SCI has relied primarily upon proceeds realized from the public and private sale of its common and preferred stock and convertible notes to meet its funding requirements. Funds raised by CEL-SCI have been expended primarily in connection with the acquisition of an exclusive worldwide license to certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, the repayment of debt, the continuation of Company-sponsored research and development, administrative costs and construction of laboratory facilities. Inasmuch as CEL-SCI does not anticipate realizing revenues until such time as it enters into licensing arrangements regarding the technology and know-how licensed to it (which could take a number of years), CEL-SCI is mostly dependent upon the proceeds from the sale of its securities to meet all of its liquidity and capital resource requirements.

In fiscal 2003, CEL-SCI reduced its discretionary expenditures. In fiscal 2004 and 2005 expenditures remained at the 2003 levels. If necessary, CEL-SCI may reduce discretionary expenditures in fiscal 2006; however such reductions would further delay the development of CEL-SCI's products.

Multikine has an FDA approved shelf life of two years. Consequently, Multikine can only be used for two years after it is manufactured. Since the last batch of Multikine was manufactured over two years ago, CEL-SCI does not currently have any Multikine available for future clinical studies. As a result, CEL-SCI will be required to manufacture additional quantities of Multikine for future research and clinical studies. CEL-SCI anticipates that the Multikine needed for its planned Phase III clinical trial will be manufactured in several batches over a two to three year period at a cost of between $4 to $5 million. CEL-SCI's last batch of Multikine was used during the fall of 2002.

Equity Lines of Credit

In order to provide a possible source of funding for CEL-SCI's current activities and for the development of its current and planned products, CEL-SCI entered into an equity line of credit agreement with Rubicon Group Ltd. in December 2003 and ending December 2005.

Under the equity line of credit agreement, Rubicon Group has agreed to provide CEL-SCI with up to $10,000,000 of funding during a two year period beginning on December 29, 2003. During this period, CEL-SCI may request a drawdown under the equity line of credit by selling shares of its common stock to Rubicon Group, and Rubicon Group will be obligated to purchase the shares. The minimum amount CEL-SCI can draw down at any one time is $100,000, and the maximum amount CEL-SCI can draw down at any one time will be determined at the time of the drawdown request using a formula contained in the equity line of credit agreement. CEL-SCI may request a drawdown once every 22 trading days, although CEL-SCI is under no obligation to request any drawdowns under the equity line of credit.

During the 22 trading days following a drawdown request, CEL-SCI will calculate the number of shares it will sell to Rubicon Group and the purchase price per share. The purchase price per share of common stock will be based on the daily volume weighted average price of CEL-SCI's common stock during each of the 22 trading days immediately following the drawdown date, less a discount of 11%.

As of October 31, 2005 CEL-SCI had received net proceeds of $724,875 from the sale of shares under the equity line of credit with the Rubicon Group.

In October 2005 CEL-SCI entered into an equity line of credit agreement with Jena Holdings LLC Ltd.

Under the equity line of credit agreement, Jena Holdings LLC has agreed to provide CEL-SCI with up to $5,000,000 of funding during a two-year period beginning on the date the shares to be sold under the line of credit have been registered with the Securities and Exchange Commission. During this two-year period, CEL-SCI may request a drawdown under the equity line of credit by selling shares of its common stock to Jena Holdings LLC, and Jena Holdings LLC will be obligated to purchase the shares. The minimum amount CEL-SCI can draw down at any one time is $100,000, and the maximum amount CEL-SCI can draw down at any one time will be determined at the time of the drawdown request using a

formula contained in the equity line of credit agreement. CEL-SCI may request a drawdown once every 22 trading days, although CEL-SCI is under no obligation to request any draw-downs under the equity line of credit.

During the 22 trading days following a drawdown request, CEL-SCI will calculate the number of shares it will sell to Jena Holdings LLC and the purchase price per share. The purchase price per share of common stock will be based on the daily volume weighted average price of CEL-SCI's common stock during each of the 22 trading days immediately following the drawdown date, less a discount of 11%.

As of February 28, 2006 the shares to be sold to Jena Holdings had not been registered with the Securities and Exchange Commission.

Future Capital Requirements

CEL-SCI plans to use its existing financial resources, the proceeds from the sale of its common stock, and proceeds from the sale of common stock under the equity line of credit agreement to fund its capital requirements during the year ending September 30, 2006.

Other than funding operating losses, funding its research and development program, and paying its liabilities, CEL-SCI does not have any material capital commitments. Material future liabilities as of September 30, 2005 are as follows:


Contractual Obligations: Years Ending September 30,
-----------------------------------
Total 2006 2007 2008
----- ---- ---- ----

Operating Leases $ 359,921 $156,067 $132,719 71,136
Employment Contracts 1,247,203 702,703 363,000 181,500
----------- --------- --------- ---------
$1,607,124 $858,770 $495,719 $252,636
========== ======== ======== ========




It should be noted that substantial additional funds will be needed for more extensive clinical trials which will be necessary before CEL-SCI will be able to apply to the FDA for approval to sell any products which may be developed on a commercial basis throughout the United States. In the absence of revenues, CEL-SCI will be required to raise additional funds through the sale of securities, debt financing or other arrangements in order to continue with its research efforts. However, there can be no assurance that such financing will be available or be available on favorable terms. It is the opinion of management that sufficient funds will be available from external financing and additional capital and/or expenditure reduction in order to meet CEL-SCI's liabilities and commitments as they come due during fiscal year 2006. Ultimately, CEL-SCI must complete the development of its products, obtain appropriate regulatory approvals and obtain sufficient revenues to support its cost structure.

CEL-SCI's cash flow and earnings are subject to fluctuations due to changes in interest rates on its certificates of deposit, and, to an immaterial extent, foreign currency exchange rates.

Critical Accounting Policies

CEL-SCI's significant accounting policies are more fully described in Note 1 to the consolidated financial statements. However, certain accounting policies are particularly important to the portrayal of financial position and results of operations and require the application of significant judgments by management. As a result, the consolidated financial statements are subject to an inherent degree of uncertainty. In applying those policies, management uses its judgment to determine the appropriate assumptions to be used in the determination of certain estimates. These estimates are based on CEL-SCI's historical experience, terms of existing contracts, observance of trends in the industry and information available from outside sources, as appropriate. CEL-SCI's significant accounting policies include:

Patents - Patent expenditures are capitalized and amortized using the straight-line method over 17 years. In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, is less than the carrying value of the asset. The amount of the impairment loss is the difference between the estimated fair value of the asset and its carrying value.

Stock Options and Warrants - In October 1996, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation (SFAS No. 123). This statement encourages but does not require companies to account for employee stock compensation awards based on their estimated fair value at the grant date with the resulting cost charged to operations. CEL-SCI has elected to continue to account for its employee stock-based compensation using the intrinsic value method prescribed in Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, and related Interpretations. In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock-Based Compensation - Transaction and Disclosure" which amends SFAS No. 123. SFAS No. 148 provided alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation and requires more prominent and more frequent disclosures in the financial statements of the effects of stock-based compensation. The Company has elected to continue to account for its employee stock-based compensation using the intrinsic value method.

Asset Valuations and Review for Potential Impairments - CEL-SCI reviews its fixed assets every fiscal quarter. This review requires that CEL-SCI make assumptions regarding the value of these assets and the changes in circumstances that would affect the carrying value of these assets. If such analysis indicates that a possible impairment may exist, CEL-SCI is then required to estimate the fair value of the asset and, as deemed appropriate, expense all or a portion of the asset. The determination of fair value includes numerous uncertainties, such as the impact of competition on future value. CEL-SCI believes that it has made reasonable estimates and judgments in determining whether its long-lived assets have been impaired; however, if there is a material change in the assumptions used in its determination of fair values or if there is a material change in economic conditions or circumstances influencing fair value, CEL-SCI could be required to recognize certain impairment charges in the future. As a result of the reviews, no changes in asset values were required.

Prepaid Expenses and Laboratory Supplies--The majority of prepaid expenses consist of bulk purchases of laboratory supplies used on a daily basis in the lab and items that will be used for future production. The items in prepaid expenses are expensed when used in production or daily activity as Research and Development expenses. These items are disposables and consumables and can be used for both the manufacturing of Multikine for clinical studies and in the laboratory for quality control and bioassay use. They can be used in training, testing and daily laboratory activities. Other prepaid expenses are payments for services over a long period and are expensed over the time period for which the service is rendered.

Derivative Instruments--The Company enters into financing arrangements that consist of freestanding derivative instruments or are hybrid instruments that contain embedded derivative features. The Company accounts for these arrangement in accordance with Statement of Financial Accounting Standards No. 133, "Accounting for Derivative Instruments and Hedging Activities", ("SFAS No. 133") and Emerging Issues Task Force Issue No. 00-19, "Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock", ("EITF 00-19"), as well as related interpretations of these standards. In accordance with accounting principles generally accepted in the United States ("GAAP"), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the statement of financial position and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and recognized at fair value with changes in fair value recognized as either a gain or loss in earnings if they can be reliably measured. When the fair value of embedded derivative features can not be reliably measured, the Company measures and reports the entire hybrid instrument at fair value with changes in fair value recognized as either a gain or loss in earnings. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models, giving consideration to all of the rights and obligations of each instrument and precluding the use of "blockage" discounts or premiums in determining the fair value of a large block of financial instruments. Fair value under these conditions does not necessarily represent fair value determined using valuation standards that give consideration to blockage discounts and other factors that may be considered by market participants in establishing fair value.

[[KERN]Codex]

-10kfiling-

http://biz.yahoo.com/e/060425/cvm10-k.html

[[KERN]Codex]

CEL-SCI Corporation Announces 2005 Financial Results
Tuesday April 25, 9:00 am ET


VIENNA, Va., April 25 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM - News) reports financial results for the fiscal year ending September 30, 2005.
ADVERTISEMENT


CEL-SCI reports a loss for fiscal year 2005 of $3,039,607 versus a net loss of $2,952,077 in fiscal year 2004. The loss per share in fiscal years 2005 and 2004 were each $0.04.

During the year ended September 30, 2005, research and development expenses increased by $288,099. The increase in research and development expense was due largely to an increase in work related to CEL-SCI's Phase III application for Multikine®. Also, during the year ended September 30, 2005, general and administrative expenses decreased by $379,736. The decrease was mostly due to a decrease in public relations and corporate presentation expenses, filing fees, travel expenses, accounting fees and legal fees, as CEL-SCI's efforts were primarily focused on the submission of the Phase III clinical trial application for Multikine. During 2005 the Company received $625,472 in settlement of a lawsuit in which the Company was not a party. The litigation involved a shareholder and three former investors in CEL-SCI. The lawsuit sought to recover short-swing profits allegedly obtained by the defendants, their investment advisor and the investment advisor's principal acting together as a group in trading CEL-SCI securities. Gain on derivative instruments for the year ended September 30, 2005 decreased by $811,632 as a number of derivative instruments either expired or were reclassified to Stockholders' Equity during the year. The financial results for the fiscal year ending September 30, 2004 have been restated to correct the accounting for certain financial instruments issued by CEL-SCI between August 18, 2001 and November 28, 2003. This restatement was of a non-cash nature. Investors are advised to read the full 10-K to understand the issues involved in this non-cash restatement.

CEL-SCI Corporation is developing new immune system-based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.


CEL-SCI CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED SEPTEMBER 30, 2005 AND 2004



2005 2004
(as restated)

GRANT REVENUE AND OTHER $269,925 $325,479

OPERATING EXPENSES:
Research and development (excluding R&D 2,229,729 1,941,630
depreciation of $96,442 and $110,297
respectively, included below)
Depreciation and amortization 190,420 198,269
General and administrative 1,930,543 2,310,279

Total operating expenses 4,350,692 4,450,178

NET OPERATING LOSS (4,080,767) (4,124,699)

GAIN (LOSS) ON DERIVATIVE INSTRUMENTS 363,028 1,174,660

OTHER INCOME 625,472 -

OTHER COSTS OF FINANCING - -

INTEREST INCOME 52,660 51,817
INTEREST EXPENSE - (53,855)

NET LOSS $(3,039,607) $(2,952,077)

NET LOSS PER COMMON SHARE
BASIC $(0.04) $(0.04)
DILUTED $(0.05) $(0.06)

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
BASIC 72,703,395 67,273,133
DILUTED 73,581,925 68,924,099

[[KERN]Codex]

26.04.06 11:22
Original-Research: CEL-SCI Corp. - von MIDAS Research GmbH

Aktieneinstufung von MIDAS Research GmbH zu CEL-SCI Corp.

Unternehmen: CEL-SCI Corp. ISIN: US1508374097

Anlass der Studie:Folgeanalyse Empfehlung: Spekulativ Kaufen seit: 26.03.2004 Kursziel: EUR 3,00 nach EUR 2,35 Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: keine Analyst: Dr.Matthias Redenbach

Mannheim, den 26.04.2006 Weiterhin als Spekulativen Kauf empfehlen die Analysten von MIDAS Research den Immunsystemspezialisten CEL-SCI Corp. (AMEX CVM / WKN 871 006) und setzen in ihrer aktuellen ausführlichen Folgeanalyse das Kursziel auf EUR 3,00 von EUR 2,35 hoch. Seit Mitte Februar habe die CEL-SCI Aktie schon um 137% auf EUR 1,01 zulegen können. Gerade noch rechtzeitig hätten die Experten von MIDAS Research damals den Titel wieder auf ihren Radarschirm genommen und zum Einstieg geraten. Jetzt läge nun eine ausführliche Analyse durch das Research-Haus vor. Die akribische Bewertungsarbeit habe sich gelohnt. Denn herausgekommen sei ein sensationelles Ergebnis: CEL-SCI sei weiterhin krass unterbewertet. Selbst wenn man konservativ einen Misserfolg von 50% für die komplette weitere Forschung unterstelle wie in der Analyse geschehen ergäbe sich ein wahrscheinlichkeitsgewichteter Unternehmenswert von EUR 3,00 je Aktie. Dabei befände sich CEL-SCI mit dem Krebspräparat Multikine bereits in der klinischen Phase III und sei mit seinen neuartigen Ansätzen zur Behandlung von Infektionen wie der Vogelgrippe darüber hinaus in aller Munde.

Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/10147.pdf Die Studie ist zudem auf www.midasresearch.de erhältlich.

Kontakt für Rückfragen MIDAS Research GmbH Michael Drepper 0621/ 430 61 30 Karl-Ladenburg-Straße 16 68163 Mannheim

-------------------übermittelt durch die EquityStory AG.-------------------


Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

[[KERN]Codex]

26.04.06 11:22
Original-Research: CEL-SCI Corp. - von MIDAS Research GmbH

Aktieneinstufung von MIDAS Research GmbH zu CEL-SCI Corp.

Unternehmen: CEL-SCI Corp. ISIN: US1508374097

Anlass der Studie:Folgeanalyse Empfehlung: Spekulativ Kaufen seit: 26.03.2004 Kursziel: EUR 3,00 nach EUR 2,35 Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: keine Analyst: Dr.Matthias Redenbach


Mannheim, den 26.04.2006 Weiterhin als Spekulativen Kauf empfehlen die Analysten von MIDAS Research den Immunsystemspezialisten CEL-SCI Corp. (AMEX CVM / WKN 871 006) und setzen in ihrer aktuellen ausführlichen Folgeanalyse das Kursziel auf EUR 3,00 von EUR 2,35 hoch. Seit Mitte Februar habe die CEL-SCI Aktie schon um 137% auf EUR 1,01 zulegen können. Gerade noch rechtzeitig hätten die Experten von MIDAS Research damals den Titel wieder auf ihren Radarschirm genommen und zum Einstieg geraten. Jetzt läge nun eine ausführliche Analyse durch das Research-Haus vor. Die akribische Bewertungsarbeit habe sich gelohnt. Denn herausgekommen sei ein sensationelles Ergebnis: CEL-SCI sei weiterhin krass unterbewertet. Selbst wenn man konservativ einen Misserfolg von 50% für die komplette weitere Forschung unterstelle wie in der Analyse geschehen ergäbe sich ein wahrscheinlichkeitsgewichteter Unternehmenswert von EUR 3,00 je Aktie. Dabei befände sich CEL-SCI mit dem Krebspräparat Multikine bereits in der klinischen Phase III und sei mit seinen neuartigen Ansätzen zur Behandlung von Infektionen wie der Vogelgrippe darüber hinaus in aller Munde.

Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/10147.pdf Die Studie ist zudem auf www.midasresearch.de erhältlich.

Kontakt für Rückfragen MIDAS Research GmbH Michael Drepper 0621/ 430 61 30 Karl-Ladenburg-Straße 16 68163 Mannheim

-------------------übermittelt durch die EquityStory AG.-------------------


Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

[[KERN]Codex]

CEL-SCI's Target Price Raised.


As we noted on the SCBLOG Monday afternoon, Midas Research of Germany released a comprehensive 16-page follow-up report on biotech CEL-SCI (AMEX: CVM).
As a result of recent corporate news and developments, Midas has raised its 12-month target for CVM shares to $3.71 versus $2.80 as noted in its previous reports. While we think that target may be somewhat conservative--as does Midas' analyst--the detailed report is both cogent and extensive.

CVM shares opened at $1.25, Tuesday.

Here's the link to the Midas report. Investors -- both new and established -- really need to take a few minutes to carefully read and review the research. A German version was also released in Europe.

We reiterate our suggestion that the shares of CVM should be accumulated for superior gains over the next 6-12 months. The profile of the shares as well as trading volumes continue to swell as more investors jockey to establish exposure to this unique story.

One interesting factor to note is that the author of the report , analyst Matthias Redenbach, is both a scientist and an economist; making his perspective on the science of CVM's flagship therapies, Multikine and CEL-1000 quite unique. It's truly fascinating information and written with the layperson in mind. There is a discussion of CVM's potential bird flu efficacy:

The current situation with the bird flu documents the potential risk stemming from rapidly mutating viral pathogens. This potential threat will not diminish in importance in the future and the development of new technologies and products for the production of vaccines and targeted immune modulators are among the most important markets in the pharmaceutical sector. The CEL-SCI researchers under Dan Zimmermann have therefore set the goal of developing a new generation of vaccines against pathogens such as malaria, AIDS, herpes and others.
Redenbach's target price is formulated as a result of constructing a series of 'success' probability scenarios for CVM's various present and future initiatives. Coupled with the use of discounted cash flow models, a conservative 12 month target price of $3.71 is derived.
Not much has changed, tech-wise from our comments on the SCBLOG on April 21. The shares continue to hover around the 3/8 retracement level of the recent large move and should momentum continue to grow from here, these levels look to be a decent entry point. CVM's trading is known for volatility and we see no reason for that to change anytime soon. Best strategy remains to keep a core position and trade the swings. Has worked out pretty well so far, or at least since we alerted the readership at 52 cents on February 10th.

As well, the Company filed its 2005 10k Tuesday morning--therefore extinguishing any regulatory concerns--which as you will recall, was quite late due to a change in accountants and focused compliance with new accounting procedures. The quarterly report should follow soon.

Not much more to report. The report is excellent on two fronts: a complete primer on the history and progress of the Company as well as a realistic and conservative construction of the compelling future potential.

It seems the major risk for investors is not having a position in CEL-SCI.

[[KERN]Codex]

Cancer Survival Data From Multikine to be Presented in May 2006
Wednesday May 10, 9:30 am ET


VIENNA, Va., May 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM - News) announces that the results of a long-term survival study of cancer patients treated with CEL-SCI's drug Multikine® will be presented at a scientific conference during May 2006. Specifically, the data relates to head & neck cancer patients treated with Multikine in a Phase II clinical trial concluded over 3.5 years ago.
ADVERTISEMENT


Data from the follow-up study indicate that Multikine treatment resulted in a substantial increase in the survival of head & neck cancer patients. In addition, Multikine treatment also improved the local regional control of the patients' tumors. Improved local regional control of the tumor is considered by many surgeons and oncologists to be an important measurement of the success of a head & neck cancer therapy. Both survival and local regional control of the tumor are stated endpoints in CEL-SCI's planned Phase III clinical trial.

The Phase II study, which used the same Multikine treatment protocol as proposed for the Phase III trial, included advanced primary head & neck cancer patients who were scheduled for their first cancer treatment. The Multikine treatment was administered for three weeks prior to the standard treatment for head & neck cancer, surgery or surgery plus radiation/chemotherapy. Results from this study were published in a leading cancer publication, the Journal of Clinical Oncology (Timar et al, JCO, 23(15): May 2005).

Head & neck cancer is an aggressive cancer that affects about 500,000 people per annum worldwide. About 92% of those cases are outside of the U.S., and about two thirds of all cases present with advanced disease.

Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines, including interleukins, interferons, chemokines and colony-stimulating factors, currently being developed for treatment of cancer.

The Company's lead product Multikine is cleared to enter global Phase III clinical trials in advanced primary head and neck cancer patients (by Canadian Regulators). CEL-SCI's other products, which are currently in pre-clinical stage and are funded with U.S. government support, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2005. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

[[KERN]Codex]

So habe nachgekauft,

0,81 USD

das wollt ich nur mal festhalten

[[KERN]Codex]

Form 10-Q for CEL SCI CORP


--------------------------------------------------------------------------------

18-May-2006

Quarterly Report



Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS
Liquidity and Capital Resources

The Company has had only limited revenues from operations since its inception in March 1983. The Company has relied upon proceeds realized from the public and private sale of its Common Stock and convertible notes as well as short-term borrowings to meet its funding requirements. Funds raised by the Company have been expended primarily in connection with the acquisition of exclusive rights to certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, the funding of Viral Technologies, Inc.'s (VTI) research and development program (inactive since 2000), patent applications, the repayment of debt, the continuation of Company-sponsored research and development and administrative costs, and the construction of laboratory facilities. Inasmuch as the Company does not anticipate realizing significant revenues until such time as it enters into licensing arrangements regarding its technology and know-how or until such time it receives permission to sell its product (which could take a number of years), the Company has been dependent upon short-term borrowings and the proceeds from the sale of its securities to meet all of its liquidity and capital resource requirements.

In June 2000, the Company entered into an agreement with Cambrex Bio Science, Inc. ("Cambrex") whereby Cambrex agreed to provide the Company with a facility which allows the Company to manufacture Multikine in accordance with the Good Manufacturing Practices regulations of the FDA for periodic manufacturing campaigns. Company personnel will staff this facility. This agreement runs until December 31, 2006.

In July and September 2002, the Company sold convertible notes, plus 900,000 Series G warrants, to a group of private investors. By June 2, 2003, all of the notes had been converted into common stock. As of December 31, 2005, 450,000 warrants had been exercised and 450,000 warrants remain outstanding. In addition, in January 2003, the Company sold convertible notes, plus Series H warrants to purchase 1,100,000 shares of common stock, to a group of private investors. By October 2, 2003, all of the Series H notes had been converted into common stock. The Series H warrant price is currently $0.25. As of December 31, 2005, 550,000 warrants had been exercised and 550,000 warrants remain outstanding.

On December 1, 2003, the Company sold 2,994,964 shares of its common stock to a group of private institutional investors for approximately $2,550,000, or $0.85 per share. As part of this transaction, the investors in the private offering received warrants which allow the investors to purchase approximately 900,000 shares of the Company's common stock at a price of $1.32 per share at any time prior to December 1, 2006. As of December 31, 2005, all warrants remain outstanding.

During April 2006, all of the remaining Series G and H warrants were converted into 618,560 shares of common stock in a cashless exercise.

On May 30, 2003, the Company and Eastern Biotech signed an agreement to develop both Multikine and CEL-1000, and their derivatives and improvements, in three Eastern European countries: Greece, Serbia and Croatia. Eastern Biotech also has the exclusive right to sales in these three countries. As part of the agreement, Eastern Biotech gained the right to receive a 1% royalty on the future net sales of these two products and their derivatives and improvements worldwide. Eastern Biotech also purchased 1,100,000 shares of common stock and warrants, which allow the holder to purchase up to 1,100,000 shares of the Company's common stock at a price equal to $0.47. The Company received proceeds of $500,000 for these shares and warrants. Because the Company did not register these shares prior to September 30, 2003, the royalty percentage increased to 2%. If Eastern Biotech did not meet certain clinical development milestones within one year, it would lose the right to sell both products in these three countries. As of June 1, 2004 no clinical trials had been started by Eastern Biotech and in accordance with the agreement, Eastern Biotech lost its exclusive right to market, distribute and sell both products in the countries.

On May 4, 2004, the Company announced the completion of an offering of 6,402,439 shares of registered common stock at $0.82 per share to one institutional investor. This sale resulted in gross proceeds of $5.25 million and associated costs of $498,452. The stock was offered pursuant to an existing shelf registration statement and Wachovia Capital Markets, LLC acted as the placement agent for the offering. The Company intends to use the proceeds of the offering to advance the clinical development of Multikine for the treatment of cancer. In addition, 76,642 warrants were issued to Wachovia at a price of $1.37 and the warrants expire May 4, 2009. The warrants were valued using the Black-Scholes valuation method and an expense of $38,127 was recorded to additional paid-in capital as a cost of equity related transaction during the fiscal year ended September 30, 2004.

In order to provide a possible source of funding for CEL-SCI's current activities and for the development of its current and planned products, CEL-SCI entered into an equity line of credit agreement with Jena Holdings LLC on October 31, 2005.

Under the equity line of credit agreement, Jena Holdings LLC has agreed to provide CEL-SCI with up to $5,000,000 of funding for a two year period which will begin on the date that a registration statement filed by CEL-SCI to register the shares to be sold to Jena Holdings LLC is declared effective by the SEC. During this two year period, CEL-SCI may request a drawdown under the equity line of credit by selling shares of its common stock to Jena Holdings LLC, and Jena Holdings LLC will be obligated to purchase the shares. The minimum amount CEL-SCI can draw down at any one time is $100,000, and the maximum amount CEL-SCI can draw down at any one time will be determined at the time of the drawdown request using a formula contained in the equity line of credit agreement. CEL-SCI may request a drawdown once every 22 trading days, although CEL-SCI is under no obligation to request any drawdowns under the equity line of credit.

During the 22 trading days following a drawdown request, CEL-SCI will calculate the amount of shares it will sell to Jena Holdings LLC and the purchase price per share. The purchase price per share of common stock will be based on the daily volume weighted average price of CEL-SCI's common stock during each of the 22 trading days immediately following the drawdown date, less a discount of 11%. As consideration for extending the equity line of credit, CEL-SCI granted Jena Holdings LLC warrants to purchase 271,370 shares of common stock at a price of $0.55 per share at any time prior to October 24, 2010. CEL-SCI will be registering the shares of common stock issuable to Jena Holdings under the equity line of credit, as well as 271,370 shares underlying the warrants that CEL-SCI granted to Jena Holdings LLC. During the three-month period ended December 31, 2005, the Company made drawdowns on the equity line of credit totaling $677,727, selling 1,419,446 shares of common stock. Subsequent to the issuance of the Company's September 30, 2004 consolidated financial statements, the Company determined that it had erroneously accounted for certain financial instruments, including free-standing and embedded derivatives within such instruments, issued by the Company from fiscal year 1992 through November 2003. Specifically, the instruments erroneously accounted for were: the Series E Preferred Stock, the Cambrex Convertible Note Payable, Series F, G and H Convertible Debt, the equity line of credit agreements, as well as Series I and J warrants and various other warrants. The Company has concluded that these instruments were either freestanding derivative instruments in their entirely, or contained embedded derivatives, and should have been accounted for under SFAS No. 133 and EITF 00-19, as well as related interpretations of these standards. All such derivatives were required to be recognized as either assets or liabilities in the statement of financial position and measured at fair value in the statement of operations. At December 31, 2005, the only remaining instrument that needs this valuation is the Series E warrants, which expire on August 16, 2006. For a further discussion of this restatement and an assessment of each instrument, please see the Company's September 30, 2005 10-K, footnote 2.

Subsequent to the issuance of the Company's September 30, 2004 consolidated financial statements, the Company determined that it had erroneously accounted for certain financial instruments, including free-standing and embedded derivatives within such instruments, issued by the Company from fiscal year 1992 through November 2003. Specifically, the instruments erroneously accounted for were: the Series E Preferred Stock, the Cambrex Convertible Note Payable, Series F, G and H Convertible Debt, the equity line of credit agreements, as well as Series I and J warrants and various other warrants. The Company has concluded that these instruments were either freestanding derivative instruments in their entirely, or contained embedded derivatives, and should have been accounted for under SFAS No. 133 and EITF 00-19, as well as related interpretations of these standards. All such derivatives were required to be recognized as either assets or liabilities in the statement of financial position and measured at fair value in the statement of operations. At December 31, 2005, the only remaining instrument that needs this valuation is the Series E warrants, which expire on August 16, 2006. For a further discussion of this restatement and an assessment of each instrument, please see the Company's September 30, 2005 10-K, footnote 2.

Results of Operations

"Grant revenues and other" decreased by $45,660 during the three months ended December 31, 2005, compared to the same period of the previous year, due to the winding down of the work funded by the grants in 2005. The Company is continuing to apply for grants to support its work.

During the three month period ended December 31, 2005, research and development expenses decreased by $266,215. In the previous year, expenses were higher because the Company was working on the Phase III application for Multikine.

During the three month period ended December 31, 2005, general and administrative expenses increased by $40,822. An increase in public relations and corporate presentation expenses and the employee stock option expense required by SFAS 123R was partially offset by a decrease in accounting fees.

Interest income during the three months ended December 31, 2005 decreased by $6,416. The decrease was because the balances in the interest bearing accounts declined.


Research and Development Expenses

During the three month periods ended December 31, 2005 and 2004, the Company's
research and development efforts involved Multikine and L.E.A.P.S.. The table
below shows the research and development expenses associated with each project
during the three-month periods.

Three Months Ended
December 31,
----------------------
2005 2004

MULTIKINE $383,897 $614,573

L.E.A.P.S. 50,992 86,531
-------- --------
TOTAL $434,889 $701,104
======== ========




In August, 2005, the Canadian regulatory agency, the Biologics and Genetic Therapies Directorate, concurred with the initiation of a global Phase III clinical trial in head and neck cancer patients using Multikine. On January 4, 2005, the Company announced that it had submitted a Phase III clinical trial protocol to the U.S. Food and Drug Administration ("FDA") for the use of its investigational immunotherapy drug Multikine in the treatment of advanced primary squamous cell carcinoma of the oral cavity. Additional information in support of and to provide the rationale for the Phase III trial (final reports of clinical trials conducted with Multikine to date and manufacturing and testing information) was included with this submission. The Company met with FDA in April of 2005 and again in October of 2005 to discuss the Phase III trial. The meeting was very useful and productive, and the Company views it as the start of a continuing dialogue with the Agency on this matter. It is clear that the FDA recognizes the need for new and improved therapies for head and neck cancer patients, and it appears to be amenable to new approaches. The Company

found the FDA's evaluation of the plan supportive and helpful. A number of specific technical aspects of the Company's development plan were discussed and the FDA made several suggestions as to how the plan could be improved. The Company provided additional information to the FDA in 2005, and is waiting for the FDA's response. The Company is unable to estimate the future costs of research and clinical trials involving Multikine since the Company has not yet finalized the design of future clinical trials. Until the scope of these trials is known, the Company will not be able to price any future trials with clinical trial organizations.

As of December 31, 2005 the Company was involved in a number of pre-clinical studies with respect to its L.E.A.P.S. technology. As with Multikine, the Company does not know what obstacles it will encounter in future pre-clinical and clinical studies involving its L.E.A.P.S. technology. Consequently, the Company cannot predict with any certainty the funds required for future research and clinical trials and the timing of future research and development projects.

Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company's clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products.

Since all of the Company's projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Critical Accounting Policies - The Company's significant accounting policies are more fully described in Note A to the financial statements. However certain accounting policies are particularly important to the portrayal of financial position and results of operations and require the application of significant judgments by management. As a result, the condensed consolidated financial statements are subject to an inherent degree of uncertainty. In applying those policies, management uses its judgment to determine the appropriate assumptions to be used in the determination of certain estimates. These estimates are based on the Company's historical experience, terms of existing contracts, observance of trends in the industry and information available from outside sources, as appropriate. Our significant accounting policies include:

Patents - Patent expenditures are capitalized and amortized using the straight-line method over 17 years. In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from disposition, is less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Stock Options and Warrants - In October 1996, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards No. 123, Accounting for Stock-Based Compensation (SFAS No. 123). This statement encourages but does not require companies to account for employee stock compensation awards based on their estimated fair value at the grant date with the resulting cost charged to operations. The Company has elected to continue to account for its employee stock-based compensation using the intrinsic value method prescribed in Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees, and related Interpretations. Options to non-employees are accounted for in accordance with FASB's Emerging Issues Task Force (EITF) Issue 96-18 Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services. Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires management to make assumptions regarding the fair value of the options at the date of grant and the expected life of the options. Using the modified prospective transition method of adoption, CEL-SCI reflects compensation expense in the financial statements beginning October 1, 2005. The modified prospective transition method does not require restatement of prior periods to reflect the impact of SFAS No. 123R. As such, compensation expense will be recognized for awards that were granted, modified, repurchased or cancelled on or after October 1, 2005 as well as for the portion of awards previously granted that vested during the quarter ended December 31, 2005. For the three months ended December 31, 2005, the Company recorded $51,798 in general and administrative expense for the cost of employee options. The Company determines the fair value of the employee compensation using the Black Scholes method of valuation. No corresponding expense was recorded for the three months ended December 31, 2004 because the statement did not require the cost to be recorded in that period.

Asset Valuations and Review for Potential Impairments - The Company reviews its fixed assets every fiscal quarter. This review requires that the Company make assumptions regarding the value of these assets and the changes in circumstances that would affect the carrying value of these assets. If such analysis indicates that a possible impairment may exist, the Company is then required to estimate the fair value of the asset and, as deemed appropriate, expense all or a portion of the asset. The determination of fair value includes numerous uncertainties, such as the impact of competition on future value. The Company believes that it has made reasonable estimates and judgments in determining whether our long-lived assets have been impaired; however, if there is a material change in the assumptions used in our determination of fair values or if there is a material change in economic conditions or circumstances influencing fair value, the Company could be required to recognize certain impairment charges in the future.

Prepaid Expenses and Laboratory Supplies--The majority of prepaid expenses consist of bulk purchases of laboratory supplies used on a daily basis in the lab and items that will be used for future production. The items in prepaid expenses are expensed when used in production or daily activity as R&D expenses. These items are disposables and consumables and can be used for both the manufacturing of Multikine for clinical studies and in the laboratory for quality control and bioassay use. They can be used in training, testing and daily laboratory activities. Other prepaid expenses are payments for services over a long period and are expensed over the time period for which the service is rendered.

[[KERN]Codex]

Bin sehr gespannt auf Montag, ich habe mir Geld beseite gepackt für gute Ergebnisse, 0,85 USD ist echt wenig für die großartigen Aussichten

Viel Erfolg weiterhin,

dranbleiben!

[[KERN]Codex]

CEL-SCI Corporation Reports Second Quarter 2006 Financial Results
Friday May 19, 9:00 am ET


VIENNA, Va., May 19 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM - News) reports financial results for the three and six months ending March 31, 2006.
The Company's net loss for the quarter ending March 31, 2006 was $1,331,071 versus a net loss of $1,149,440 during the same quarter in 2005. The Company's net loss for the six months ended March 31, 2006 was $2,328,198 versus a net loss of $2,378,883 during the same six months in 2005.

"Grant revenue and other" decreased by $72,970 and $118,630 during the three and six months ended March 31, 2006, respectively, compared to the same periods of the previous year.

During the three month period ended March 31, 2006, research and development charges decreased by $158,030 compared to the same period in 2005. During the six month period ended March 31, 2006, research and development expenses decreased by $424,245 compared to the same period in 2005.

During the three month period ended March 31, 2006, general and administrative expenses increased by $346,929 compared to the same period in 2005. This increase in the loss is due to the costs for the restatement of prior year financials that CEL-SCI completed in April 2006. During the six month period ended March 31, 2006, general and administrative expenses increased by $387,751 compared to the same period in 2005.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.




CEL-SCI CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)
Three Months Ended
March 31,
2006 2005
REVENUES:
Grant revenue and other $36,815 $109,785

EXPENSES:
Research and development, excluding
depreciation of $18,511 and $29,447
included below 426,857 584,887
Depreciation and amortization 43,635 53,089
General and administrative 907,570 560,641

Total Operating Expenses 1,378,062 1,198,617

NET OPERATING LOSS (1,341,247) (1,088,832)

GAIN (LOSS) ON DERIVATIVE INSTRUMENTS (1,822) (75,082)

INTEREST INCOME 11,998 14,474

NET LOSS $(1,331,071) $(1,149,440)

NET LOSS PER COMMON SHARE (BASIC) $(0.02) $(0.02)

NET LOSS PER COMMON SHARE (DILUTED) $(0.02) $(0.02)

WEIGHTED AVERAGE COMMON
SHARES OUTSTANDING 78,392,835 72,287,847




CEL-SCI CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)
Six Months Ended
March 31,
2006 2005
REVENUES:
Grant revenue and other $66,662 $185,292

EXPENSES:
Research and development excluding
depreciation of $37,021 and $63,099
included below 861,746 1,285,991
Depreciation and amortization 87,425 109,768
General and administrative 1,480,606 1,092,855

Total Operating Expenses 2,429,777 2,488,614

NET OPERATING LOSS (2,363,115) (2,303,322)

GAIN (LOSS) ON DERIVATIVE INSTRUMENTS 11,515 (107,855)

INTEREST INCOME 23,402 32,294

NET LOSS $(2,328,198) $(2,378,883)

NET LOSS PER COMMON SHARE (BASIC) $(0.03) $(0.03)

NET LOSS PER COMMON SHARE (DILUTED) $(0.03) $(0.03)

WEIGHTED AVERAGE COMMON
SHARES OUTSTANDING 76,677,015 72,232,732




--------------------------------------------------------------------------------
Source: CEL-SCI Corporation

[[KERN]Codex]

[Tscholle]

stay long and have fun !

[Tscholle]

Antwort auf Beitrag Nr.: 21.731.392 von Tscholle am 21.05.06 21:04:04

http://www.baz.ch/news/index.cfm?ObjectID=48626210-1422-0CEF…

[nort.]

CEL-SCI Presents Long-Term Survival Data With Its Anti-Cancer Drug Multikine(R)

VIENNA, Va., May 23 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) announces the presentation of long-term survival data from its Phase II clinical trial in patients with head & neck cancer (oral squamous cell carcinoma -- OSCC) treated with its anti-cancer drug Multikine(R). The addition of Multikine as first-line treatment prior to the standard of care treatment resulted in a 33-40% improvement in the median survival at 3 1/2 years post-surgery, when compared to the results of 39 OSCC clinical trials published in the scientific literature between 1987 and 2004. The data were presented at the "Vaccine Discovery and Commercialization" conference in Philadelphia, PA.

The long-term survival data were collected by the treating physicians in a follow-up study of 22 patients with advanced untreated primary tumors, who were enrolled in the Multikine Phase II clinical trial. The Multikine treatment regimen was administered to these patients prior to the standard of care treatment (i.e., surgery + radiation or surgery + chemo-radiation). Informed consent was obtained from all patients in the clinical trial and from 19 patients for the long-term follow-up study. Investigational Review Board / Ethics Committee approval was provided before the initiation of the clinical trial and again for the data collection in the follow-up study. The follow-up study questionnaire assessed the overall survival and the local regional control of the Multikine treated patients in this Phase II trial.

Documented data were available for 19 of the 22 patients in the follow-up portion of this clinical trial. Of the three patients who could not be evaluated in the follow-up study, one patient was known to be alive, but failed to give informed consent, and the other two were lost to follow-up. One patient died the day after definitive surgery, unrelated to Multikine therapy.

The median overall survival (calculated by including death from any cause of patients in the trial, even deaths not related to the disease) of the 19 evaluable patients in the follow-up portion of this clinical trial was 63% at a median follow-up of 40 months post-surgery. The results of the published scientific literature (39 OSCC clinical trials published between 1987 and 2004) document that survival at 3 1/2 years is approximately 47% following standard of care treatment. The addition of Multikine to the standard of care treatment resulted in a 33% increase in overall survival over the results published in the literature.

The median survival of patients in this clinical trial was 67% at a median follow-up of 42 months post-surgery, excluding the one patient with immediate post-operative death. The same 39 scientific publications indicate that survival at 3 1/2 years is approximately 47% following standard of care treatment. The addition of Multikine to the standard of care treatment resulted in an increase in survival of 40% over the results published in the literature.

Multikine first-line treatment also resulted in a 2-year local regional control (LRC) rate of 79%, as compared to the median 2-year LRC of 73% reported in the same 39 scientific publications. Multikine treatment resulted in an improvement over the published local regional control rate. It is clinically recognized that recurrence of disease in head & neck cancer is associated with a very poor prognosis.

Multikine treatment did not result in any severe adverse events (SAE) in this Phase II clinical trial. No SAEs related to Multikine have been reported in other trials conducted with Multikine either.

The data from CEL-SCI\'s Multikine Phase II clinical trial are thought to be directly applicable to CEL-SCI\'s planned global Phase III clinical trial, as the Multikine treatment regimen planned in the Phase III trial is identical to that of the Multikine treatment in the trial reported here. Furthermore, the planned endpoints of the Phase III trial are local regional control, disease-free survival and overall survival, all of which have shown improvement compared to historical controls, following Multikine first-line treatment over the current available treatments for these patients.

Head & neck cancer is an aggressive cancer that affects 500,000 people per annum worldwide, and approximately 2/3 of patients present with advanced disease.

Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally-occurring human cytokines, including interleukins, interferons, chemokines and colony-stimulating factors, currently being developed for the treatment of cancer.

CEL-SCI Corporation, with operations in Vienna, VA and Baltimore, MD is developing new immune system based treatments for cancer and infectious diseases. CEL-SCI\'s other products are currently in the pre-clinical stage of development. Pre-clinical animal studies have received U.S. government support. The results of these studies indicate these products may offer protection against a number of diseases. The agents are being tested, among others, against diseases associated with bio-defense and avian (bird) flu.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company\'s potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation\'s SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2005. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

SOURCE CEL-SCI Corporation
-0- 05/23/2006
/CONTACT: Gavin de Windt of CEL-SCI Corporation, [phone], or
Investor Relations: Mike Lucci of Lucci Financial Group, LLC, [phone],
for CEL-SCI Corporation/
/Web site: http://www.cel-sci.com /

[[KERN]Codex]

Juhuu und ich hab nachgekauft

Das ist das Fundament für die Phase III Zulassung..

[[KERN]Codex]

Das warten wird sich bezahlt machen

Wünsche eine gute Nacht


p.s.

NEW in the last 5 minutes

Flu vaccine stocks hit Hong Kong Standard 00:06


15 to 30 minutes old

Agriculture Department's lab in Ames, Iowa, prepares for bird flu testing Santa Barbara News Press, California 23:52 23-May-06

Two more deaths from bird flu as Indonesia tries to track down souce of... News-Medical.Net 23:40 23-May-06


30 minutes to 1 hour old

Firms still failing to plan for worst The Bath Chronicle, Somerset 23:28 23-May-06

PPA calls for interest-free loans Daily Times 23:21 23-May-06

Iran denies human bird flu cases Daily Times 23:21 23-May-06

Dog Flu Could Strike Western Pennsylvania Soon KDKA, Pennsylvania 23:13 23-May-06


1 to 2 hours old

Possible Human-to-Human Transmission of Avian Flu in Indonesia SportsBlog (Weblog) 23:09 23-May-06

Probe into possible human-to-human bird flu spread Stuff.nz 22:53 23-May-06

Possible human to human bird flu The Raw Story 22:48 23-May-06

Human to Human Bird Flu transmission? The Big Picture (Weblog) 22:35 23-May-06

Possible human transmission of bird flu probed MSNBC 22:33 23-May-06



Sixth Member of Indonesian Family Dies from Bird Flu Washington File 22:32 23-May-06

Here Comes The Bird Flu Epidemic (?) Microsoft's Channel 9 (Weblog) 22:30 23-May-06


2 to 4 hours old

Scientists Study New Technique to Vaccinate Birds Against Avian Flu Voice of America News 22:09 23-May-06

Human-to-human bird flu suspected   WorldNetDaily 22:06 23-May-06

Health officials to talk about bird flu tonight The News-Press, Florida 21:52 23-May-06

Study Warns of "Chaos" and "Panic" If Bird Flu Strikes ConsumerAffairs.Com 21:18 23-May-06

Logan To Guard Against Bird Flu TheBostonChannel.com, Massachusetts 21:17 23-May-06



Fears of human-to-human bird flu spread Ninemsn 21:16 23-May-06

WHO probes bird flu spread The Daily Telegraph, New South Wales 21:08 23-May-06

Romania Urges Calm After Avian Flu Outbreak Radio Free Europe 20:46 23-May-06

WHO probes possible human-to-human bird flu spread Reuters via Yahoo! US 20:38 23-May-06

WHO: Avian Flu Rapidly Spreading in Birds Around World Voice of America News 20:35 23-May-06



BPA: Presents Positive Data re Avian Flu Vaccine at Med Conf Today.. American Stock Exchange (Press Release) 20:30 23-May-06

WHO probes possible human-to-human bird flu Reuters 20:29 23-May-06

'No mutation' in bird flu strain news.com.au 20:15 23-May-06

Work on faster virus detection news.com.au 20:15 23-May-06

Market Report -- In Play (BPA) CNBC 20:10 23-May-06



Upsnap Provides Cell-Phone Emergency Alert The Post Chronicle 20:10 23-May-06

[nort.]

Vogelgrippe: Tausende in Bukarest unter Quarantäne
Maßnahme gilt für bis zu drei Wochen

Nach der Bestätigung eines Vogelgrippe-Falles sind mehr als 13.000 Bewohner der rumänischen Hauptstadt Bukarest unter Quarantäne gestellt worden. Die Maßnahme gelte für einen Zeitraum von ein bis drei Wochen, sagte der Bürgermeister des südlich gelegenen vierten Bezirks, Adrian Inimaroiu. Alle Geschäfte und Behörden in dem Viertel blieben in dieser Zeit geschlossen. Etwa 2500 Vögel in der Gegend würden so schnell wie möglich getötet.

Polizisten und Soldaten sperrten die Zugangsstraßen ab. Das rumänische Landwirtschaftsministerium hatte zuvor bestätigt, dass in der Region das Virus in mehreren toten Hühnern gefunden worden sei. Am Sonntagabend war bereits eine Gegend in den nördlichen Vorstädten von Bukarest unter Quarantäne gestellt worden. In den vergangenen zehn Tagen waren laut Landwirtschaftsministerium 38 Vogelgrippe-Fälle in Rumänien festgestellt worden. In 26 weiteren Fällen ist das Virus noch nicht offiziell bestätigt.

http://www.mittelbayerische.de/SID_2e0c1c48ab2ded70267a7c08f…

[[KERN]Codex]

1,23 USD


Name
Cel-sci Corp

Last Price
1.2300

Net Change
+0.3800
+0.1600 (AH)

Last Match Time
19:57:19.477
Market
AM

Previous Close
0.8500

Percent Change
+44.71%
+14.95 (AH)

[[KERN]Codex]

CEL-SCI makes headway with lead drug
3/3/2006 11:45:44 AM
By Robert Ilich Associate Editor




Geert Kersten
CEO

In the dynamic biopharmaceutical industry, the value of one drug can make or break a company.

Fortunately for CEL SCI Corporation (AMEX: CVM Quotes, News, Charts), it’s lead drug, Multikine, is helping to “make” the company.

The Virginia-based company recently announced positive results from a long-term follow-up study of head & neck cancer patients treated with Multikine in a Phase II clinical trial.

“These results suggest that Multikine has the potential to bring much needed benefit to patients with head and neck cancer, a disease that has significant morbidity and mortality and for which there has been little improvement in therapy over the last 20 years,” said Maximilian de Clara, President of CEL-SCI in a recent press release. “We are very excited by these results and hope to repeat these very promising results in our Phase III clinical trial."

CEL SCI also recently announced it has signed an agreement with the National Institutes of Health to test a possible avian flu vaccine
based on one of its drugs. But it is in the recent cancer study that has the company buzzing.

“This is one field where data wins,” said Geert Kersten, Chief Executive Officer of CEL-SCI Corporation. “We can prove in a Phase III study, in a statistically-significant manner, that our drug does something that other drugs cannot do. We will have created value, not just to the patients, but also to the investors, that is just beyond belief. It is that basic premise that keeps us moving forward.”

According to Kersten, the company is looking to “raise a good chunk of money.” The company recently reported that it has entered into a definitive agreement with one investor to raise $1,000,000 through the sale of 2,500,000 shares of its common stock at a price of 40 cents per share.

"This investment group has been a great supporter of ours for several years,” Kersten said in a press release. “We are pleased to have them invest in CEL-SCI again.”

Investors have been bullish on CEL SCI since the onset of 2006. Since the beginning of the year, the company’s share price has increased roughly 60 percent.

Ultimately, the company believes the advantages in Multikine, and its ability to improve on already established treatments, will boost the company’s future profits.

“Our idea is, not to replace the current treatment, but add our Multikine to the current treatment and give you, instead of a 50 percent chance of survival, a 60 to 70 percent chance,” Kersten said. “ Since our drug is not specific to any one type of tumor…you ought to apply it to other types of cancer also, particularly cancers where you have the same first treatment.”

[[KERN]Codex]

Aktien kaufen wenn sie keiner haben will

[Jerome2509]

Antwort auf Beitrag Nr.: 24.734.266 von [KERN]Codex am 20.10.06 09:14:09

Hey Kerni,

bin mal vom Molo-Forum hierher abgewandert.
Der prof könnte sich mal von Briefen von Herr Kersten was abschneiden..

Sag mal wie siehst Du eigentlich die beiden Ansätze von Cel-Sci mit Multikine und Molo? Ist das vom Grundsatz her nicht das gleiche Prinzip?

[[KERN]Codex]

Antwort auf Beitrag Nr.: 24.804.261 von Jerome2509 am 23.10.06 18:17:50

Hey

ich werde es der IR mal nahelegen, wenn Mologen über den Berg ist, weil solche Geschichten wirklich Vertrauen schaffen und man langfristig gebunden wird, auch emotional

Grundlegend ist die Geschichte hier dieselbe, nur das hier mit einem Cocktail aus verschiedenen Immunstimulierenden Geschichten gearbeitet wird, neben dem Interleukin, auch Cytokine, Interferone und Chemokine usw.

Vom Ansatz her aber ähnlich, und wie Phase 2 gezeigt hat, sehr erfolgsversprechend!

Warst du es nicht der in Richtung Biotech studiert?

grüsse aus Hamburg

kerni

[[KERN]Codex]

September 2006

Dear Fellow Shareholders:

Many of us invest in biotechnology because of its life changing possibilities and its enormous potential for financial return. We all know that the development of a biotech drug takes a long time, is difficult and costs many millions of dollars. Yet most of us are willing to wait for the potential “home run” on our investment as long as the data looks good. However, the cyclical and at times completely illogical treatment of biotechnology stocks by the investment community challenges the commitment of even the most dedicated of investors.

For this reason we are very pleased to point out that CEL-SCI’s share price has outperformed the vast majority of its small and mid cap brethrens, albeit with enormous cyclical volatility, over the last few years. Since high volatility will never be eliminated from biotech stocks like CEL-SCI, we must learn to use it to our advantage. I recently purchased more stock in the open market because I believe that the present price represents a great opportunity.

In the spring of 2003 CEL-SCI’s financial health looked rather bleak, our stock price hit an all time low and few people believed in our ability to survive, much less rebound. Nevertheless, despite a stock market environment that has been quite unfriendly to small and medium sized biotechnology companies like ours, we have managed to put ourselves on good financial footing and increased our share price by several hundred percent; and that is after CEL-SCI’s stock price pulled back from its substantially higher level in the spring of 2006. We survived, and indeed improved our position by persistently and carefully following our plan for building shareholder value and obeying the following rule. “FOLLOW THE DATA, THE DATA NEVER LIE.”

The data for CEL-SCI’s products point to a very positive future for our company. Furthermore, based upon our most recent survival data and our cautious and deliberate way of proceeding, we believe that we will continue to build value for our shareholders. Management’s sizable investment in CEL-SCI gives us added incentive to do so.

We aim to make the first line cancer treatment more successful through the addition of our cancer drug Multikine®. Multikine will be a major breakthrough in therapy for cancer patients if we can confirm the increased patient survival data from our Phase II clinical studies in the planned global Phase III clinical study that has already received the go-ahead by the Canadian authorities. Simplistically, would you rather have a 65 - 70% chance of survival with our Multikine or a 50% chance of survival without our Multikine? When we can prove this kind of clinical benefit to patients, shareholder value creation will need no further explanation.

We believe that the market for Multikine may quickly expand beyond the original head and neck cancer indication. The product has already been shown to be very safe, and it is very probable that clinical trials will be conducted with Multikine to examine its usefulness in treating other diseases in which the affected patients might benefit by the addition of Multikine to their overall treatment. Furthermore, the use of Multikine, especially in cancer, would save the health care system money, most likely a lot of money, as fewer patients will have recurrence of their cancer, and thus fewer patients will need to be treated. In short, Multikine could become a very important addition to current cancer treatments.

In the last 18 months we have achieved a number of very important milestones for Multikine. We have published the mechanism of action in the Journal of Clinical Oncology, a highly recognized, leading peer-reviewed cancer publication. We have been granted an important new patent on Multikine, and we received a no objection letter (NOL) from the highly regarded Canadian regulators for our Multikine Global Phase III head and neck cancer clinical trial. Last, but not least, we presented data at the "Vaccine Discovery and Commercialization" conference in Philadelphia which indicate that the addition of Multikine prior to the standard of care treatment resulted in a 33-40% improvement in the median survival at 3 1/2 years after surgery. Survival is the “gold standard” for testing in cancer.

Our CEL-1000 drug has also received a fair amount of attention. It has shown protection in animals against a number of diseases such as herpes virus, viral encephalitis, malaria and leishmania. Based on these data, the U.S. government became interested in its potential for use against avian flu. We believe that CEL-1000 may have the best avian flu potential in two areas, one, as an adjuvant to make vaccines more effective and two, as an adjunct to other antiviral therapies. Either of these uses holds great promise for CEL-1000 as a product.

We cannot say that the past years have been without difficulties, far from it, but we have been able to overcome any obstacles that we have encountered. We believe that future obstacles will also be dealt with in the same manner. If developing new medicines for cancer were easy, cancer would have been defeated long ago; after all, President Nixon declared the war on cancer 36 years ago. Yet cancer is the second leading cause of death in the U.S. today and, if the trend continues, it is expected to become the leading cause of death in the next few years.

Today we continue to believe that our CEL-SCI shares are not fully valued by the market place, an unhappy occurrence for existing shareholders, but a great opportunity for new shareholders. This is not an uncommon phenomenon in biotechnology investing and was seen often during the early days of Amgen or Genentech, today’s leading biotechnology companies. Now almost everybody wishes that they had been long-term investors in Amgen or Genentech since these companies turned out to be great investments. In hindsight the successes of these biotech leaders may appear to have been easy, but an examination of their early history reveals that things did not always go their way. Until 2003 Genentech seemed to be the only one who believed in Avastin, its new blockbuster cancer drug. These companies succeeded because they were persistent and they followed the data. We plan to do the same.

What is the value of a non-toxic cancer drug that enhances survival? To cancer patients it is immeasurable. To investors it is so big that they want to be invested in the company that owns it. That is why I have invested so much of my own money in CEL-SCI, with new stock purchases just a short time ago.

Our Phase II data suggest that we have a cancer compound that may significantly increase survival in patients with advanced primary head and neck cancer. Our Phase III trial is meant to prove this survival benefit in a statistically significant manner to get Multikine approved for sale.

In short, we hope to be able to build significant shareholder value by conducting our important work in a deliberate and methodical manner and always following the data. This has worked for us in the past few years and it should continue to work for us in the future as well. We thank you for your support.

Sincerely,

Geert Kersten
Chief Executive Officer

[Plaste]

Kann es sein das das ShortRation Verhältnis langsam steigt?
Wir sind bei 5,2.
Vor einigen Wochen war das wenn ich mich recht erinnere noch weit weniger wie die hälfte. Oder täusche ich mich da?
Hat das noch jemand beobachtet???


Nur zur Info:
Short Interest Ratio = Summe aller leerverkauften Papiere dividiert durch den durchschnittlichen Tagesumsatz. Die Kennziffer gibt an, wie viele Tage nötig sind, um alle leerverkauften Aktien einzudecken.


mfg Plaste

[ALF-FRED]

Subject: Why is FDA stalling CEL-SCI's cancer drug?
To: [e-mail]
A very promising cancer therapy in late stage testing needs your help. Please write to the FDA (e-mail and mail address provided below):

A small US biotechnology company, CEL-SCI Corporation ( www.cel-sci.com... ), has had a very promising cancer drug pending for a Phase III (final study) approval before the FDA for 22, yes you are reading correctly, 22 months. This same application was approved by the Canadian regulators in only 2 months. The Canadians and the FDA are supposed to use the same approval standards. What is the FDA doing? Please let the FDA know that this is not right. Cancer patients are dying while the FDA is delaying.
The Company has spent $90 million to develop this product called Multikine. The FDA has previously allowed studies with Multikine in head & neck cancer, prostate cancer, cervical dysplasia and HIV-infected patients, at a time when there was no safety data and no survival data. In these studies Multikine was shown to be very safe and in head & neck cancer it increased long-term survival by about 40%. Since the Company was allowed to study the product when there was no safety or survival data and the Canadian FDA has already approved the study, one has to wonder why the FDA is not moving ahead. One has to hope that the influence of certain big pharmaceutical firms is not that strong at FDA. The only beneficiaries from Multikine’s delay are the big pharmaceutical companies who would lose cancer product sales.
Let CEL-SCI run its Phase III clinical trial with Multikine and let the chips fall where they may!!!! If the drug turns out to be just half as good as it was in Phase II trials, it will be a breakthrough saving many lives.
The goal of Multikine is to make the first cancer treatment more successful. This means that Multikine would cure more patients with the first treatment. The Phase II clinical trial with Multikine showed about a 40% improvement in survival from Multikine. Anyone who has ever had cancer, or has a family member or friend with cancer, knows that recurrence of the cancer is bad, very bad. Multikine is designed to stop that recurrence.
Multikine cured 12% of head & neck cancer patients in 3 weeks, with no toxicity. Anyone who has ever seen the effects of radiation and chemotherapy can tell you how very amazing that is. On average Multikine killed 50% of the tumor cells in just a few weeks. It appears to enhance the killing of cancer cells with radiation and chemotherapy.
CEL-SCI’s results were published in leading peer-reviewed journals. The Canadians approved the Phase III study in 2 months. Why is the drug not allowed to move forward with excellent safety and promising efficacy data when it was allowed to move forward when there was no data? Is the drug, now that there is promising data, a threat to someone?
Please write to the FDA and let them know that you find this delay unacceptable. A safe cancer drug with promise should not be held up for politics. Too many people are dying of cancer every day. FDA finally has a new Commissioner, Dr. Andrew von Eschenbach. He probably does not even know about this travesty. Let him know and ask him to look into this. He can make a difference. Please contact him today.

Please write to the Commissioner as a concerned citizen and ask him to move CEL-SCI’s application along so that Multikine gets a chance to prove itself in Phase III studies. Patients are dying and there is a drug that looks like it could help a good number of them.

[e-mail]

or

Office of the Commissioner, FDA
Parklawn Building HF-1
Room 1471
5600 Fishers Lane
Rockville, MD 20857

Please forward this letter to as many of your friends as possible and post it on chat board or blogs.

[[KERN]Codex]

Antwort auf Beitrag Nr.: 25.113.600 von ALF-FRED am 04.11.06 07:10:10

danke

[ALF-FRED]

Antwort auf Beitrag Nr.: 25.175.040 von [KERN]Codex am 06.11.06 14:38:20

Wofür habe ich bei Yahoo gefunden

[[KERN]Codex]

Antwort auf Beitrag Nr.: 25.175.192 von ALF-FRED am 06.11.06 14:48:34

Ja fürs reinstellen..

[ALF-FRED]

da könnten ja mal Infos kommen

CEL-SCI CEO to Present at the Life Science Informed Investor Forum


VIENNA, Va., Nov. 10 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION
(Amex: CVM), a drug development company with its lead cancer product
cleared for a Phase III trial in Canada, announced that its Chief Executive
Officer, Geert Kersten, is a featured presenter at the Life Science
Informed Investors On-line Forum. The webcast presentation is scheduled for
Tuesday, November 14, 2006 at 11:00 a.m. (Eastern Daylight Time) and can be
accessed via the Internet at http://www.informedinvestors.com.
CEL-SCI Corporation is developing new immune system based treatments
for cancer and infectious diseases. The Company has operations in Vienna,
Virginia and Baltimore, Maryland. The Company\'s lead product Multikine(R)
is cleared to enter global Phase III clinical trials in advanced primary
head and neck cancer patients. CEL-SCI\'s other products, which are
currently in pre- clinical stage and are funded with U.S. government
support, have shown protection against a number of diseases in animal tests
and are being tested against diseases associated with bio-defense and avian
flu.



SOURCE CEL-SCI Corporation

[ALF-FRED]

Webcast Alert: CEL-SCI Corp. Announces Its Informed Investors Forum Webcast
CEL-SCI Corp. (AMEX: CVM) announces the following Webcast: What: CEL-SCI Corp. Informed Investors Forum Webcast When: November 14, 2006 @ 11:00 AM Eastern Where: http://www.investorcalendar.com/EventPage.asp?ID=111447" target="_blank" rel="nofollow ugc noopener">http://www.investorcalendar.com/EventPage.asp?ID=111447 How: Live over the Internet -- Simply log on to the web at the address above.

Contact: Gavin de Windt, 703-506-9460 or [e-mail] If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=111447" target="_blank" rel="nofollow ugc noopener">http://www.investorcalendar.com/ClientPage.asp?ID=111447 or http://www.investorcalendar.com/ CEL-SCI Corporation is a pioneer in biotechnology research. We develop novel drugs for the treatment of cancer and infectious diseases. Our lead product, Multikine®, is designed to improve first line therapy for the treatment of head & neck cancer. The concept behind Multikine is to harness the power of the immune system against cancer. Multikine is a biologic comprised of cytokines that stimulate the human immune system to overcome tumor tolerance.

CEL-SCI recently announced that Multikine demonstrated a 33–40% increase in the median survival at 3 ½ years post-surgery in head & neck cancer patients when administered as a local injection, outpatient, prior to standard first-line therapy, in Phase II trials. Local/regional control also improved. The patients were all diagnosed with advanced untreated primary tumors.

Multikine is cleared in Canada for a Phase III clinical trial designed to improve first line therapy for advanced primary head & neck cancer. The endpoints of the study are survival and local regional control.

Head & neck cancer accounts for 5% of all cancers worldwide, with 500,000 new cases each year worldwide. The potential market exceeds $1 billion.

CEL-SCI’s Asian partner, Orient Europharma, will either be running a separate Phase III study with Multikine in head & neck cancer or will share the costs of the Phase III study with CEL-SCI. The Far East has a very large number of head & neck cancer patients.

Another patented CEL-SCI technology called L.E.A.P.S.™, and its lead candidate CEL-1000, have enjoyed significant government funding as well as collaborations with the U.S. Navy, U.S. Army and National Institutes of Health (NIH). CEL-1000 has been shown to protect against viruses and parasitic diseases in animals.

In December 2005, CEL-SCI signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to test CEL-1000 against the avian (bird) flu virus H5N1 in animal models.

CEL-SCI is listed on the AMEX under the stock symbol CVM.

CEL-SCI Corp. (AMEX: CVM) announces the following Webcast:

What: CEL-SCI Corp. Informed Investors Forum Webcast

When: November 14, 2006 @ 11:00 AM Eastern

Where: http://www.investorcalendar.com/EventPage.asp?ID=111447" target="_blank" rel="nofollow ugc noopener">http://www.investorcalendar.com/EventPage.asp?ID=111447

How: Live over the Internet -- Simply log on to the web at the address above.

Contact: Gavin de Windt, 703-506-9460 or [e-mail]

If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=111447" target="_blank" rel="nofollow ugc noopener">http://www.investorcalendar.com/ClientPage.asp?ID=111447 or http://www.investorcalendar.com/

CEL-SCI Corporation is a pioneer in biotechnology research. We develop novel drugs for the treatment of cancer and infectious diseases. Our lead product, Multikine(R), is designed to improve first line therapy for the treatment of head & neck cancer. The concept behind Multikine is to harness the power of the immune system against cancer. Multikine is a biologic comprised of cytokines that stimulate the human immune system to overcome tumor tolerance.

CEL-SCI recently announced that Multikine demonstrated a 33-40% increase in the median survival at 3 1/2 years post-surgery in head & neck cancer patients when administered as a local injection, outpatient, prior to standard first-line therapy, in Phase II trials.

Local/regional control also improved. The patients were all diagnosed with advanced untreated primary tumors.

Multikine is cleared in Canada for a Phase III clinical trial designed to improve first line therapy for advanced primary head & neck cancer. The endpoints of the study are survival and local regional control.

Head & neck cancer accounts for 5% of all cancers worldwide, with 500,000 new cases each year worldwide. The potential market exceeds $1 billion.

CEL-SCI's Asian partner, Orient Europharma, will either be running a separate Phase III study with Multikine in head & neck cancer or will share the costs of the Phase III study with CEL-SCI. The Far East has a very large number of head & neck cancer patients.

Another patented CEL-SCI technology called L.E.A.P.S.(TM), and its lead candidate CEL-1000, have enjoyed significant government funding as well as collaborations with the U.S. Navy, U.S. Army and National Institutes of Health (NIH). CEL-1000 has been shown to protect against viruses and parasitic diseases in animals.

In December 2005, CEL-SCI signed an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to test CEL-1000 against the avian (bird) flu virus H5N1 in animal models.

CEL-SCI is listed on the AMEX under the stock symbol CVM.

[ALF-FRED]

http://www.investorshub.com/boards/board.asp?board_id=61

[ALF-FRED]

Cel Sci CEL-SCI Announces the Development and Patenting of a New Platform Technology to Treat Immune System-Based Diseases
Datum : 19/12/2006 @ 17:12
Quelle : PR Newswire
Name : Cel Sci Cp (CVM)
Kurs : 0.62 0.07 (12.73%) @ 17:12
<< Zurück Kurs Chart Reports Trades Level2


Cel Sci CEL-SCI Announces the Development and Patenting of a New Platform Technology to Treat Immune System-Based Diseases



VIENNA, Va., Dec. 19 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (AMEX:CVM) announces the development and patenting of a new platform technology for the treatment of a number of major diseases including autoimmune disease, asthma, allergy and transplant rejection. CEL-SCI recently received a notice of allowance from the U.S. patent office protecting this technology.

This breakthrough T-cell modulation platform technology is called "AdapT," which stands for "Antigen Directed Apoptosis." AdapT technology uses proprietary two-peptide molecular constructs to selectively cause the death of only those immune T-cells that are involved in autoimmune disease, asthma, allergy, and transplant rejection, by having these disease causing T-cells undergo apoptosis (programmed cell death) and anergy (a state of immune unresponsiveness).

It has been well established in the scientific literature that at least two signals are required for T-cell activation and that, if only one signal is supplied to T-cells without the ability of the same T-cells to receive a second activation signal, the T-cells undergo "programmed cell death." The AdapT molecular constructs capitalize on this well known principle and "work" by engaging the antigen-specific T-cell receptor with one of its peptides and, at the same time, block and inhibit the second signal needed for the full activation of these disease causing T-cells. This single engagement (T-cell receptor occupation), in the absence of the required "second signal" for T- cell activation, causes these antigen-specific disease causing T-cells to self-destruct and die, thereby leading to the treatment and prevention of these diseases.

The advantage of the AdapT technology derives from its ability to selectively remove the disease causing T-cell clones from the host (humans and animals) following the administration of the AdapT construct(s). Current treatments of these diseases generally utilize non-specific immunosuppressants or immunomodulatory compounds or cytokines. The use of an antigen-specific technology to regulate the immune response and the T-cells causing disease has a distinct advantage over the use of non-specific immunosuppressants because the AdapT technology should limit or even eliminate the unwanted side effects of the currently available immunosuppressant drugs.

Dr. Eyal Talor, Senior Vice President of Research and Manufacturing at CEL-SCI and the inventor of this technology said, "The AdapT technology provides for a way to target only those T-cells that cause disease. This new approach should give us the ability to markedly decrease or completely retard the disease process, and at the same time avoid the negative effects on the healthy part of the immune system -- thus, treating the disease and at the same time keeping the rest of the immune response intact."

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company's lead product Multikine(R) is cleared to enter global Phase III clinical trials in advanced primary head and neck cancer patients. CEL-SCI's other products, which are currently in pre- clinical stage and have been funded with U.S. government support, have shown protection against a number of diseases in animal tests and are currently being tested against diseases associated with bio-defense and avian flu.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, inability to get American Stock exchange approval for any transaction and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2005. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

DATASOURCE: CEL-SCI Corporation


CONTACT: Gavin de Windt of CEL-SCI Corporation, [phone]


Web site: http://www.cel-sci.com/

[ALF-FRED]

Kerni es geht los

Press Release Source: CEL-SCI Corporation


CEL-SCI Receives Green Light From FDA to Proceed With Phase III Cancer Study
Tuesday January 16, 10:00 am ET


VIENNA, Va., Jan. 16 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM - News), (Germany: LSR) today announced that the U.S. Food and Drug Administration (FDA) has stated in a letter to the Company that, "...the proposed Phase III study may proceed at any time." CEL-SCI's Phase III clinical study is designed to prove that its cancer drug Multikine® increases the survival of head and neck cancer patients.
ADVERTISEMENT


The study is expected to be conducted in numerous countries around the world. It is designed to develop conclusive evidence of the efficacy of the Multikine treatment regimen in advanced primary squamous cell carcinoma of the oral cavity (head and neck cancer). Upon successful completion of this study, the data will be included in CEL-SCI's worldwide Marketing Applications to make Multikine commercially available for the treatment of this patient population. Head and neck cancer is an aggressive disease affecting about 500,000 people per annum worldwide.

Geert Kersten, Chief Executive Officer of CEL-SCI, said, "So far Multikine has been shown to be non-toxic, which is very unusual for a cancer drug. In Phase II clinical studies with head and neck cancer patients it also markedly increased survival. Now we will get the chance to prove that Multikine can extend the survival of these cancer patients."

The global Phase III study will test the hypothesis that the Multikine treatment regimen, administered locally prior to the current standard therapy given to patients with advanced primary squamous cell carcinoma of the oral cavity, will extend the overall survival and enhance the local/regional control of the disease, while increasing disease free survival in these patients.

Multikine is a patented immunotherapeutic agent consisting of a defined mixture of naturally occurring cytokines, including interleukins, interferons, chemokines and colony-stimulating factors.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, inability to get American Stock exchange approval for any transaction and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2005. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date thereof or to reflect the occurrence of unanticipated events.




--------------------------------------------------------------------------------
Source: CEL-SCI Corporation

[[KERN]Codex]

CEL-SCI Receives Positive Signal From FDA To Proceed With Phase III Cancer Study - Quick Facts
Tuesday January 16, 2007 10:30:00 EST


(RTTNews) - CEL-SCI Corp. (CVM) said it has received positive signal from Food and Drug Administration to Proceed With Phase III Cancer Study. CEL-SCI\'s Phase III clinical study is designed to prove that its cancer drug Multikine increases the survival of head and neck cancer patients.


The company noted that the study is designed to develop conclusive evidence of the efficacy of the Multikine treatment regimen in advanced primary squamous cell carcinoma of the oral cavity (head and neck cancer). Upon successful completion of this study, the data will be included in CEL-SCI\'s worldwide Marketing Applications to make Multikine commercially available for the treatment of this patient population.


Geert Kersten, Chief Executive Officer of CEL-SCI, said, "So far Multikine has been shown to be non-toxic, which is very unusual for a cancer drug. In Phase II clinical studies with head and neck cancer patients it also markedly increased survival. Now we will get the chance to prove that Multikine can extend the survival of these cancer patients."


The company stated that the global Phase III study will test the hypothesis that the Multikine treatment regimen will extend the overall survival and enhance the local/regional control of the disease, while increasing disease free survival in these patients.


Multikine is a patented immunotherapeutic agent consisting of a defined mixture of naturally occurring cytokines, including interleukins, interferons, chemokines and colony-stimulating factors.


Copyright(c) 2007 RealTimeTraders.com, Inc. All Rights Reserved

[[KERN]Codex]

jeeah!!

[seehfahrer]

Antwort auf Beitrag Nr.: 26.960.258 von ALF-FRED am 16.01.07 16:50:57

Meister Kern,wie bewertest du nachstehende Meldung,hast du noch weitergehende Informationen!? Bin vor zwei Tagen nach sehr langem Warten raus und nun wieder zu 0,55 rein.Lege großen Wert auf deine Einschätzung. MfG S.

[[KERN]Codex]

Nutzt die chance

leute

13:59:07 0,145 527611

[wurmdobler]

unser überraschungsei! :-) ! Gruß an Alfred


ISIN: US1508374097

Anlass der Studie:Update wg. Phase-III-Studie Empfehlung: Spekulativ Kaufen seit: 26.03.2004 Kursziel: EUR 2,35 Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: keine Analyst: Dipl.-Bio. Claudia Meissner Mannheim, den 16.02.2006 In ihrem aktuellen Company Profile erneuern die Experten von MIDAS Research ihre Spekulativ Kaufen Einschätzung für den Immunsystemspezialisten CEL-SCI Corp. (AMEX CVM / WKN 871 006). CEL-SCI habe von der kanadischen Behörde Biologics and Genetics Therapies Directorate (BGTD) die Bestätigung zur Durchführung klinischer Phase-III-Studien mit dem Hauptpräparat Multikine in Kanada erhalten. Eine vergleichbare Genehmigung durch die US-amerikanische Zulassungsbehörde FDA werde erwartet. Damit könne CEL-SCI zu den wenigen Biotechnologiefirmen aufschließen, die ein neuartiges Krebspräparat in der späten klinischen Entwicklung haben und sich damit - vor Mitbewerben - einen wichtigen strategischen Vorteil sichern. Die Analysten gingen deshalb davon aus, dass der stark gedrückte Aktienkurs von CEL-SCI spätestens auf die Nachricht einer FDA-Zulassung der Phase-III-Studie für Multikine oder eine vergleichbare Nachricht, die als weitere signifikanter Proof-of-concept zu sehen ist mit erheblichen Aufschlägen reagieren dürfte. Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/10122.pdf Die Studie ist zudem auf www.midasresearch.de erhältlich. Kontakt für Rückfragen MIDAS Research GmbH Michael Drepper 0621/ 430 61 30 Karl-Ladenburg-Straße 16 68163 Mannheim -------------------übermittelt durch die EquityStory AG DGAP.------------------- Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.


Quelle: dpa-AFX

[[KERN]Codex]

Antwort auf Beitrag Nr.: 26.981.424 von [KERN]Codex am 17.01.07 14:01:13

falscher Thread,

zu cvm

ich warte auf das cel sci statement und auf den exacten start der studie, phase 3 wird auch für übernahmen interessant, man sollte auch verstärkt das auge auf insiderkäufe und generell auf größere blöcke werfen, jetzt wird es interessant, solange die aktie keiner haben will sollte man sukzessive zukaufen, genau wie der ceo

[ALF-FRED]

Cel Sci CEL-SCI Corporation Announces 2006 Financial Results
Datum : 17/01/2007 @ 14:01
Quelle : PR Newswire
Name : Cel Sci Cp (CVM)
Kurs : 0.7 0.0 (0.00%) @ 15:01
<< Zurück Kurs Chart Reports Trades Level2


Cel Sci CEL-SCI Corporation Announces 2006 Financial Results



VIENNA, Va., Jan. 17 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (AMEX:CVM) reports financial results for the fiscal year ending September 30, 2006.

CEL-SCI reports a net operating loss for fiscal year 2006 of $5,349,196 versus a net operating loss of $4,080,767 in fiscal year 2005.

During the year ended September 30, 2006, general and administrative expenses increased by about $1,476,000. The increase was mostly due to: 1) costs related to the restatement of the financial statements, 2) an increase in public relations and corporate presentation expenses, 3) an increase in filing and registration fees and 4) the employee stock option expense required by SFAS 123R. Many of the expenses listed above are non-cash charges.

The issuance of the Series K convertible debt in the summer of 2006 resulted in an additional charge of approximately $4,791,500. This charge included $568,710 paid as fees to the agent, legal fees and $223,907 in placement warrants issued to the agent. The remaining $3,998,800 (approximate) represent the immediate charge upon issuance of the convertible debt for the fair value accounting for the debt and the warrants. This charge is a non-cash charge. The interest expense of $216,737 is a result of the amortization of the discount on the convertible debt ($104,351) and actual interest paid in stock and cash ($112,386) for the interest expense on the Series K convertible debt.

The gain on derivative instruments of approximately $2,325,800 for the year ended September 30, 2006 was the result of several factors: 1) a decrease in the value of the stock between the date of the issuance (August 2006) of the Series K convertible debt and September 30, 2006 resulted in the biggest part of the gain (approximately $2,311,000), 2) reclassification to equity of all previous derivative instruments (approximately $13,300), and 3) expiration of the Series E warrants (approximately $1,500). CEL-SCI's future financial statements are expected to show significant gains and losses on derivative instruments due to the requirement to mark the value of the convertible debt to market, as measured by the stock price of CEL-SCI's common stock.

CEL-SCI Corporation is developing new immune system-based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.

CEL-SCI CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS YEARS ENDED SEPTEMBER 30, 2006 and 2005


2006 2005

GRANT REVENUE AND OTHER $125,457 $269,925

OPERATING EXPENSES: Research and development (excluding R&D depreciation of $74,043 and $96,442 respectively, included below) 1,896,976 2,229,729 Depreciation and amortization 170,902 190,420 General & administrative 3,406,775 1,930,543

Total operating expenses 5,474,653 4,350,692

NET OPERATING LOSS (5,349,196) (4,080,767)

GAIN ON DERIVATIVE INSTRUMENTS 2,325,784 363,028

COSTS ASSOCIATED WITH CONVERTIBLE DEBT (4,791,548) -

OTHER INCOME - 625,472

INTEREST INCOME 92,487 52,660

INTEREST EXPENSE (216,737) -

NET LOSS BEFORE INCOME TAXES $(7,939,210) $(3,039,607)

INCOME TAX PROVISION - -

NET LOSS $(7,939,210) (3,039,607)

NET LOSS PER COMMON SHARE BASIC $(0.10) $(0.04) DILUTED $(0.11) $(0.05)

WEIGHTED AVERAGE COMMON SHARES OUTSTANDING BASIC 78,971,290 72,703,395 DILUTED 93,834,078 73,581,925

See notes to consolidated financial statements.


DATASOURCE: CEL-SCI Corporation


CONTACT: Gavin de Windt of CEL-SCI Corporation, [phone]


Web site: http://www.cel-sci.com/

[[KERN]Codex]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[[KERN]Codex]

[Plaste]

[rk1901]

Antwort auf Beitrag Nr.: 28.510.696 von Plaste am 27.03.07 05:58:31

[Plaste]

Antwort auf Beitrag Nr.: 28.531.925 von rk1901 am 27.03.07 23:29:42

@ rk1901,

gestern Abend gabs ja wohl nix zu meckern

[rk1901]

Hallo ist noch jemand da, oder bin ich der Einzige der noch Aktien von der Kursrakete hat!!
Dann kann ich ja das Licht ausmachen, Tschüsssssssss

[Tscholle]

Antwort auf Beitrag Nr.: 28.660.159 von rk1901 am 04.04.07 15:20:12

STOP

NICHT das Licht ausschalten:
http://www.happyyuppie.com/cgi-bin/de/search.pl?isin=US15083…

[Tscholle]

Antwort auf Beitrag Nr.: 28.660.159 von rk1901 am 04.04.07 15:20:12

tja an meiner Party ('PartyGaming') geht halt nichts dran vorbei

[Plaste]

bin auch noch da...

[Tscholle]

Antwort auf Beitrag Nr.: 28.666.895 von Plaste am 04.04.07 20:32:43

ich auch noch ein wenig ...
(nebenher läuft ChampionsLeague)

[Tscholle]

Antwort auf Beitrag Nr.: 28.531.925 von rk1901 am 27.03.07 23:29:42

CEL-SCI to Present at Major Cancer Conference
April 4, 2007 - 12:28 PM

[Tscholle]

Antwort auf Beitrag Nr.: 28.531.925 von rk1901 am 27.03.07 23:29:42

Dr. Eyal Talor of CEL-SCI has been invited to speak at the First International Congress of the International Academy of Oral Oncology in Amsterdam, May 17-20, 2007.


http://www.drugnewswire.com

[Tscholle]

Antwort auf Beitrag Nr.: 28.666.895 von Plaste am 04.04.07 20:32:43

at Plaste

bist doch nicht mehr da ?
Bist bei PartyGaming, Bwin, oder wo treibst Dich herum



Falls doch nicht --> hier noch 'ne News:
... Dan Zimmerman is senior vice president of R&D, cellular immunology at Cel-Sci Corporation in Baltimore. Ken Rosenthal is professor of microbiology, immunology, and biochemistry at Northeastern Ohio Universities College of Medicine. Eyal Talor is senior vice president of research and manufacturing at Cel-Sci.


http://www.the-scientist.com

[Plaste]

Antwort auf Beitrag Nr.: 28.667.586 von Tscholle am 04.04.07 21:12:17

Hallo Tscholle,

bin z.Z aktiv bei:

Arques
D+S Europe
Klöckner und Co (Call)
Intercell
AVAN
CEL SCI
INHIBITEX

Da bin ich voll ausgelastet

[Tscholle]

Antwort auf Beitrag Nr.: 28.668.297 von Plaste am 04.04.07 21:55:37

Hallo Plaste,

hört sch gut an - 'alter Schwede' ...

bín bei

PartyGaming
Fluxx
Bwin
UraniumStar
Xethanol
Cel-SCI

im Spiel

[Plaste]

Antwort auf Beitrag Nr.: 28.695.432 von Tscholle am 06.04.07 21:24:41

stehtst wohl auf die Zockbuden

UnraniumStar,
werd ich mir mal anschauen.

mfg Plaste

PS: Frohe Oster aus Hessen

[Tscholle]

Antwort auf Beitrag Nr.: 28.704.078 von Plaste am 07.04.07 05:33:23

Eieieieieieiei - endlich ist die Eier-Sucherei vorbei !!!


@Plaste
Tja, Du hast recht - Zockbuden - da könnte ich meinen 'allerhint.....' darauf wetten

PartyGaming wird der Knüller in 2007 (warte mal ab bis die Welt v. der WTO Entscheidung erste Lüfte verspürt :kiss

[[KERN]Codex]

eieieie bald kommt phase drei

[[KERN]Codex]

Sollte mal ne Gegenbewegung geben..

[ALF-FRED]

Antwort auf Beitrag Nr.: 30.873.392 von [KERN]Codex am 27.07.07 11:23:35

jep, es wird langsam Zeit

[[KERN]Codex]